Anti-CD40l antibody and use thereof in treatment of human autoimmune diseases
Patent Information
- Application Number
- MYPI2025006630
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-28
- Filing Date
- 2024-04-26
- Publication Date
- 2024-10-28
AI Technical Summary
Existing CD40L-targeting antibodies have safety risks and insufficient biological activity in clinical applications. In particular, the effector function of the Fc region is difficult to completely remove, resulting in thrombotic events and poor pharmacokinetics.
High-affinity CD40L-targeting antibodies were screened through mouse hybridoma technology, and Fc mutation technology (L234A/L235A/ΔP329) was used to remove the binding ability of the Fc region of the antibody to FcγRs while retaining the affinity to FcRn to form an IgG molecular form. of antibodies.
It achieves safer pharmacokinetic characteristics and stronger biological activity, effectively blocks the CD40L/CD40 signaling pathway, reduces the risk of immunogenicity, and significantly inhibits CD40L/CD40-mediated biological functions.
Smart Images

Figure PI2025006630_DRAWING_001 
Figure PI2025006630_DRAWING_002 
Figure PI2025006630_DRAWING_003
Abstract
Description
Anti-CD40L antibodies and their applications in the treatment of human autoimmune diseases
[0001] The present invention relates to novel antibodies and antibody fragments that specifically bind to CD40L, as well as compositions containing such antibodies or antibody fragments. The present invention also relates to nucleic acids encoding such antibodies or antibody fragments, host cells containing such antibodies, and related uses. Furthermore, the present invention relates to therapeutic and diagnostic uses of these antibodies and antibody fragments.
[0002] Background of the Invention
[0003] CD40 ligand (CD40L), also known as CD154, gp39, TNF-related activation protein (TRAP), 5c8 antigen, or T-BAM, is a 39-kDa type II transmembrane protein. CD40L is a member of the tumor necrosis factor (TNF) superfamily and exists as a homotrimer on the cell membrane. It is primarily expressed on activated T cells, but is also present on other immune and non-immune cell types, such as epithelial cells, monocytes, dendritic cells, fibroblasts, smooth muscle cells, endothelial cells, and platelets. The CD40L / CD40 signaling pathway mediates a variety of immune and inflammatory responses and plays a critical role in normal immune responses. Existing studies have shown that the CD40L / CD40 signaling pathway not only mediates signaling between various lymphocytes but also participates in interactions between non-immune cells. Therefore, the CD40L / CD40 signaling pathway plays an important pathogenic role in a variety of chronic inflammatory diseases, such as autoimmune diseases, neurodegenerative diseases, graft-versus-host disease, tumors, and atherosclerosis.
[0004] Currently, several antibodies or protein drugs targeting CD40 / CD40L have shown positive therapeutic effects in clinical practice. Ruplizumab (CN101072587B), an early antibody targeting CD40L, has shown good therapeutic effects in diseases such as systemic lupus erythematosus and lupus nephritis, but its development was stopped due to the occurrence of serious safety events such as thrombosis (Nat. Med. 6 (2) (2000) 114). Subsequent studies have shown that thrombotic events are mainly caused by the formation of immune complexes between free CD40L and antibodies, which then interact with C1q and FcgR, especially FcgRIIa expressed on platelets, inducing platelet activation and aggregation, leading to the occurrence of thrombotic events. Therefore, completely removing the Fc region effector function is crucial for the safety of anti-CD40L antibodies.
[0005] All subsequent CD40L-targeting antibodies entering clinical trials have modified the Fc region. Two main approaches are employed: one is to weaken the effector function of the Fc region through mutations; the other is to completely remove the Fc region while simultaneously extending the molecule's half-life through other techniques. However, both approaches present certain challenges. The first approach, exemplified by frexalimab (AU2016294417B2), utilizes the C220S / C226S / C229S / P238S and E269R / K322A mutations, respectively, to weaken the effector function of the Fc region. However, subsequent studies have shown that these mutations cannot completely eliminate the effector function of the Fc region, thus posing safety risks. The second approach, exemplified by dapirolizumab pegol (US8293237B2) and dazodalibep (CN101679521B), retains only the monovalent anti-CD40L Fab and extends its half-life through cross-linking with PEG. However, this monovalent molecule weakens its biological activity, and PEG crosslinking also increases the difficulty of achieving CMC. Dazodalibep uses a non-traditional antibody-based Tn3 backbone protein as a molecule for targeted inhibition of CD40L, and extends the molecule's half-life by fusing it to albumin. However, clinical studies have shown that this molecule is highly immunogenic, posing certain safety risks.
[0006] Therefore, drugs targeting CD40 / CD40L, especially antibody drugs, that have better safety, retain the pharmacokinetic characteristics of antibody drugs, and at the same time have stronger biological activity are desired.
[0007] SUMMARY OF THE INVENTION
[0008] The present invention provides an antibody or fragment thereof (e.g., an antigen-binding fragment) targeting CD40L. Specifically, the present invention screens novel, high-affinity antibodies targeting CD40L using mouse hybridoma technology. Furthermore, the present invention provides mutation technology and mutants generated using this technology, which, while retaining the traditional IgG molecular form, completely eliminate the effector functions (ADCC, ADCP, CDC) mediated by the Fc region, while also reducing safety risks. Specifically, the present invention provides antibodies targeting CD40L using different Fc mutation technologies (mutation sites L234A / L235A / ΔP329).
[0009] The antibodies in the embodiments of the present invention exhibit improved safety. Specifically, the antibodies utilize an IgG molecular format. Through Fc mutation technology, the Fc region of the antibody is completely depleted of its ability to bind to all FcγRs, while retaining affinity for FcRn. Consequently, the antibodies and their fragments retain the favorable pharmacokinetic properties of antibodies while reducing their immunogenicity and safety risks.
[0010] On the other hand, the antibodies in the embodiments of the present invention also exhibit enhanced biological activity. Specifically, the high-affinity antibodies and fragments thereof targeting CD40L obtained through screening can more effectively block the CD40L / CD40 signaling pathway and / or the biological functions mediated thereby. Therefore, these antibodies and fragments thereof exhibit superior biological activity.
[0011] In some embodiments, the present invention relates to an anti-CD40L antibody or an antigen-binding fragment thereof, comprising:
[0012] (i) the three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH as shown in SEQ ID NO: 4, and the three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL as shown in SEQ ID NO: 10; or
[0013] (ii) three complementarity determining regions HCDR1, HCDR2, and HCDR3 contained in the VH as shown in SEQ ID NO: 16, and three complementarity determining regions LCDR1, LCDR2, and LCDR3 contained in the VL as shown in SEQ ID NO: 21;
[0014] For example, wherein the HCDR1 is determined according to a combination of Kabat and Chothia, and the HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are determined according to Kabat.
[0015] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof, comprising a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), a third heavy chain complementarity determining region (HCDR3), and a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3), wherein:
[0016] (i) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise or consist of the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9; or
[0017] (ii) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or respectively consist of the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20.
[0018] In some embodiments, the present invention relates to an anti-CD40L antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH), wherein the heavy chain variable region comprises an amino acid sequence having at least 90% identity with an amino acid sequence selected from SEQ ID NO: 4 or 16, or consists of said sequence, or comprises an amino acid sequence selected from SEQ ID NO: 4 or 16, or consists of said sequence.
[0019] In some embodiments, the present invention relates to an anti-CD40L antibody or an antigen-binding fragment thereof, which comprises a light chain variable region (VL), wherein the light chain variable region comprises an amino acid sequence having at least 90% identity with an amino acid sequence selected from SEQ ID NO: 10 or 21, or consists of said sequence, or comprises an amino acid sequence selected from SEQ ID NO: 10 or 21, or consists of said sequence.
[0020] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein
[0021] (i) the heavy chain variable region comprises, or consists of, an amino acid sequence of SEQ ID NO:4, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises, or consists of, an amino acid sequence of SEQ ID NO:10 that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0022] (ii) the heavy chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 21, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0023] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein
[0024] (i) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 4, and the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 10; or
[0025] (ii) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 16, and the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 21.
[0026] In some embodiments, the invention relates to an anti-CD40L antibody or antigen-binding fragment thereof comprising an Fc region.
[0027] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof, wherein the Fc region is derived from human IgG Fc, e.g., Fc from human IgG1, Fc from human IgG2, Fc from human IgG3, or Fc from human IgG4.
[0028] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof, wherein the Fc region comprises a mutation that reduces or eliminates effector function and / or a mutation that eliminates binding to FcγR while retaining binding affinity to FcRn. In some embodiments, the mutations are L234A / L235A and P329 deletion mutations. In some embodiments, the Fc region
[0029] (i) comprising or consisting of the amino acid sequence of SEQ ID NO: 23 or 24;
[0030] (ii) comprises an amino acid sequence that is at least 90% identical, such as 95%, 96%, 97%, 99% or more identical to the amino acid sequence of SEQ ID NO: 23; or
[0031] (iii) comprising an amino acid sequence that is at least 90% identical, such as 95%, 96%, 97%, 99% or more identical to the amino acid sequence of SEQ ID NO: 24, and comprises the L234A / L235A and P329 deletion mutations.
[0032] In some embodiments, the present invention relates to an anti-CD40L antibody or an antigen-binding fragment thereof, which comprises a heavy chain constant region, wherein the heavy chain constant region is derived from the constant region of IgG1, IgG2, IgG3 or IgG4. Preferably, the heavy chain constant region
[0033] (i) comprises or consists of an amino acid sequence selected from SEQ ID NO: 5 or 26;
[0034] (ii) comprises an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 26; or
[0035] (iii) comprising an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 5, and having L234A / L235A and P329 deletion mutations.
[0036] In some embodiments, the present invention relates to an anti-CD40L antibody or an antigen-binding fragment thereof, which comprises a light chain constant region, wherein the light chain constant region is a lambda or kappa light chain constant region, preferably, the light chain constant region
[0037] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 11; or
[0038] (ii) comprising or consisting of the amino acid sequence of SEQ ID NO: 11.
[0039] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof comprising a heavy chain, wherein the heavy chain
[0040] (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 6 or 17; or
[0041] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 6 or 17.
[0042] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof comprising a light chain, wherein the light chain
[0043] (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 12 or 22; or
[0044] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 12 or 22.
[0045] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein
[0046] (i) the heavy chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 6; and the light chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12;
[0047] (ii) the heavy chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 17; and the light chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 22.
[0048] In some embodiments, the present invention relates to an anti-CD40L antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein
[0049] (i) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 6, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 12;
[0050] (ii) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 17, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 22.
[0051] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a humanized antibody or a chimeric antibody. In some embodiments, the antigen-binding fragment is an antibody fragment selected from the group consisting of: Fv, Fab, Fab', Fab'-SH, F(ab')2, dAb (domain antibody), linear antibody, single-chain antibody (e.g., scFv); single-domain antibody (sdAb) such as VHH, diabody or fragment thereof, or camelid antibody or diabody.
[0052] In some embodiments, the anti-CD40L antibody or antigen-binding fragment thereof has one or more of the following properties:
[0053] a) binds to CD40L (e.g., human CD40L) with high affinity;
[0054] b) Inhibit the binding of CD40 to CD40L
[0055] c) inhibiting the CD40 / CD40L signaling pathway;
[0056] d) inhibiting B cell activation or proliferation;
[0057] e) inhibiting the proliferation of B cells;
[0058] f) inhibiting B cell maturation and differentiation, such as inhibiting B cell differentiation into plasma cells;
[0059] g) inhibiting the secretion of IL-12 by dendritic cells;
[0060] h) does not cause platelet activation;
[0061] i) treatment or prevention of immune diseases, such as multiple sclerosis (MS); and / or
[0062] j) suppressing immune responses, preferably humoral immune responses, such as suppressing the production of antibodies
[0063] k) improved pharmacokinetics, preferably having an in vivo half-life equal to or greater than about 200 hours, more preferably equal to or greater than about 210, 220, 230, 240, 250, 260, 270, 280, or 290 hours.
[0064] In some embodiments, the present invention relates to an isolated nucleic acid encoding an anti-CD40 antibody or antigen-binding fragment thereof of the present invention. In some embodiments, the present invention relates to a vector comprising the nucleic acid, preferably an expression vector.
[0065] In some embodiments, the present invention relates to a host cell comprising a nucleic acid of the present invention or a vector of the present invention. Preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from yeast cells, mammalian cells (e.g., 293 cells or CHO cells, such as CHO-K cells or HEK293 cells) or other cells suitable for preparing antibodies or antigen-binding fragments thereof.
[0066] In some embodiments, the present invention relates to a method for preparing an anti-CD40L antibody or an antigen-binding fragment thereof, the method comprising
[0067] 1) culturing the host cell of the present invention under conditions suitable for expressing the nucleic acid encoding the anti-CD40L antibody or antigen-binding fragment thereof of the present invention,
[0068] m) optionally isolating the antibody or antigen-binding fragment thereof,
[0069] n) Optionally, the method further comprises recovering the anti-CD40L antibody or antigen-binding fragment thereof from the host cell. Optionally, the antibody is purified, for example, by Protein A purification.
[0070] In some embodiments, the present invention relates to an immunoconjugate comprising an anti-CD40L antibody of the present invention or an antigen-binding fragment thereof and other substances, such as therapeutic agents, such as active agents that produce biological effects, including but not limited to cytokines, other antibodies, small molecule drugs or immunomodulators (e.g., immunosuppressants).
[0071] In some embodiments, the present invention relates to a pharmaceutical composition comprising an anti-CD40L antibody or antigen-binding fragment thereof of the present invention or an immunoconjugate of the present invention, and optionally a pharmaceutically acceptable excipient.
[0072] In some embodiments, the present invention relates to a composition comprising an anti-CD40L antibody of the invention or an antigen-binding fragment thereof, or an immunoconjugate of the invention, and one or more other therapeutic agents, such as active agents that produce a biological effect, including but not limited to cytokines, other antibodies, small molecule drugs, or immunomodulators (e.g., immunosuppressants).
[0073] In some embodiments, the present invention relates to a method for preventing or treating a disease or condition associated with inappropriate activation of a CD40L / CD40-mediated pathway in an individual, the method comprising administering to the subject an effective amount of an anti-CD40L antibody or antigen-binding fragment thereof, or immunoconjugate, or pharmaceutical composition, or pharmaceutical combination product of the present invention.
[0074] In some embodiments, the subject has abnormal activation of a CD40L / CD40-mediated signaling pathway and / or excessive production and deposition of anti-self antibodies compared to a healthy individual; and / or the subject has increased expression of CD40L or CD40 on cells (e.g., activated T cells or other types of immune cells or non-immune cells, such as epithelial cells, monocytes, dendritic cells, fibroblasts, smooth muscle cells, endothelial cells, and platelets), e.g., compared to corresponding cells in a healthy individual.
[0075] In some embodiments, the disease or disorder is selected from an autoimmune disease, lupus nephritis, immune thrombocytopenic purpura (ITP), transplant rejection, Crohn's disease, inflammatory bowel disease (IBD), colitis, asthma / allergy, atherosclerosis, myasthenia gravis, multiple sclerosis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, coronary heart disease, type 1 diabetes, amyotrophic lateral sclerosis (ALS), and an immune response to a recombinant drug product, such as hemophilia Factor VII. Description of the drawings:
[0076] FIG1 shows that the antibodies of the present invention inhibit the binding of CD40 to CD40L at the molecular level.
[0077] FIG2 shows that the antibodies of the present invention inhibit the downstream signal activation of Jurkat cells overexpressing CD40 at the cellular level.
[0078] FIG3 shows the inhibition of the expression of CD86, a B cell activation marker, by the antibodies of the present invention.
[0079] FIG4 shows the effect of the antibodies of the present invention on the proliferation of B cells isolated in vitro.
[0080] FIG5 shows the effect of the antibodies of the present invention on the differentiation of B cells into plasma cells.
[0081] FIG6 shows the effect of the antibodies of the present invention on the secretion of IL-12 by moDC cells.
[0082] Figures 7-9 show that the antibodies of the present invention do not induce platelet activation in in vitro experiments.
[0083] Figures 10-12 show data for the antibodies of the present invention in an experimental autoimmune encephalomyelitis (EAE) mouse model.
[0084] FIG13 shows that the antibodies of the present invention inhibit the production of anti-hemocyanin antibodies in mice.
[0085] FIG14 shows the pharmacokinetics of the antibodies of the present invention in mice.
[0086] Detailed Description of the Invention
[0087] I. Definition
[0088] Before describing the present invention in detail below, it should be understood that the present invention is not limited to the specific methodology, protocols and reagents described herein, as these may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs.
[0089] To interpret this specification, the following definitions will apply, and wherever appropriate, terms used in the singular may also include the plural, and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0090] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0091] As used herein, the term "and / or" means any one of the alternatives or two or more or all of the alternatives.
[0092] As used herein, the terms "comprising" or "including" are intended to include the recited elements, integers, or steps, but do not exclude any other elements, integers, or steps. In this document, when the terms "comprising" or "including" are used, unless otherwise indicated, combinations of the recited elements, integers, or steps are also encompassed. For example, when reference is made to an antibody variable region "comprising" a specific sequence, it is intended to encompass an antibody variable region consisting of that specific sequence.
[0093] The term "CD40L" refers to a ligand expressed on activated T cells. Other names known in the art include CD154, CD40 ligand (CD40L), CD40 counter-receptor (CD40CR), gp39, T-BAM, T-cell activation molecule, TRAF, TNF-related activator protein (TRAP), and tumor necrosis factor ligand superfamily member 5 (TNFSF5). These terms are used interchangeably throughout this application. In some embodiments, the amino acid sequence of CD40L is as shown in Uniport P29965. In some embodiments, CD40L comprises the sequence shown in SEQ ID NO: 27.
[0094] The terms "whole antibody" or "full-length antibody" are used interchangeably herein and refer to antibody molecules with the structure of natural immunoglobulin molecules. In the case of conventional four-chain IgG antibodies, the full-length antibody comprises two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. In the case of heavy chain antibodies having only heavy chains and lacking light chains, the full-length antibody comprises two heavy chains (H) interconnected by disulfide bonds. For conventional four-chain IgG antibodies, the full-length antibody heavy chain is generally composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region, wherein the heavy chain constant region comprises at least three domains CH1, CH2 and CH3. The full-length antibody light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region, wherein the light chain constant region consists of the domain CL. Each heavy chain variable region VH and each light chain variable region are composed of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody fragment" includes a portion of an intact antibody. In a preferred embodiment, the antibody fragment is an antigen-binding fragment.
[0095] The term "antigen-binding fragment" of an antibody is a molecule, distinct from a full-length antibody, that comprises a portion of the full-length antibody but is capable of binding to the antigen of the full-length antibody or competing with the full-length antibody (i.e., the full-length antibody from which the antigen-binding fragment is derived) for antigen binding. Antigen-binding fragments can be prepared by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, dAb (domain antibody), linear antibodies, single-chain antibodies (e.g., scFv); single-domain antibodies (sdAb) such as VHH, diabodies or fragments thereof, or camelid antibodies or diabodies. For example, Fab fragments can be obtained by papain digestion of a full-length antibody. In addition, pepsin digestion of a full-length antibody below the disulfide bonds in the hinge region produces F(ab')2, a dimer of Fab', a divalent antibody fragment. F(ab')2 can be reduced under neutral conditions by breaking the disulfide bonds in the hinge region, thereby converting the F(ab')2 dimer into a Fab' monomer. The Fv fragment is composed of the VL and VH domains of a single antibody arm. The two domains VL and VH of the Fv fragment can be encoded by independent genes, but recombinant methods can also be used to connect the two domains using a synthetic linker peptide to produce them as a single protein chain, and in the single protein chain, the VL region and the VH region are paired to form a single-chain Fv (scFv).
[0096] "Fab fragment" or "Fab" are used interchangeably herein to refer to an immunoglobulin fragment composed of two polypeptide chains comprising an immunoglobulin heavy chain variable domain VH, a heavy chain constant domain CH1, a light chain variable domain VL, and a light chain constant domain CL, wherein one polypeptide chain comprises, from N-terminus to C-terminus, VH and a constant region selected from CH1 and CL, and the other polypeptide chain comprises, from N-terminus to C-terminus, VL and another constant region selected from CL and CH1, wherein the VH domain and the VL domain pair to form an antigen binding site. Herein, the Fab polypeptide chain comprising the heavy chain constant region CH1 is also referred to as the "Fab heavy chain"; accordingly, the Fab polypeptide chain comprising the light chain constant region CL is also referred to as the "Fab light chain."
[0097] "Diabodies" are small, bivalent antibodies constructed through gene fusion, for example, dimers composed of two polypeptide chains. The VL and VH domains of each polypeptide chain of a diabody are linked by a linker, so that the VL and VH encoded in the same polypeptide chain form a dimer with different single-chain variable region segments. Diabodies generally have two antigen-binding sites.
[0098] "Complementarity determining region" or "CDR region" or "CDR" is a region in an antibody variable domain that is highly variable in sequence and forms structurally determined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of the heavy and light chains are typically referred to as CDR1, CDR2, and CDR3, and are numbered sequentially starting from the N-terminus. The CDRs located within the antibody heavy chain variable domain are referred to as HCDR1, HCDR2, and HCDR3, while the CDRs located within the antibody light chain variable domain are referred to as LCDR1, LCDR2, and LCDR3. In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment schemes, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics database (IMGT) (on the World Wide Web at imgt.cines.fr / ), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures.
[0099] Unless otherwise indicated, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined in any of the above ways or combinations thereof. CDRs can also be determined based on having the same Kabat numbering position as a reference CDR sequence (e.g., any of the exemplary CDRs of the present invention). Unless otherwise indicated, in the present invention, when referring to residue positions in an antibody variable region (including heavy chain variable region residues and light chain variable region residues), it refers to the numbering position according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
[0100] In some embodiments, the CDRs of the heavy chain variable region of the antibodies of the present invention are determined according to Kabat or Chothia, or a combination of Kabat and Chothia. In some embodiments, the CDRs of the light chain variable region of the antibodies of the present invention are determined according to Kabat.
[0101] In some embodiments, the CDR1 of the heavy chain variable region of the antibody of the present invention is determined according to the combined scheme of Kabat and Chothia (hereinafter referred to as "Kabat and Chothia combination", corresponding to H26-H32 under the Kabat numbering system), and the CDR2 and CDR3 of the heavy chain variable region, and the LCDR1, LCDR2 and LCDR3 of the light chain variable region are determined according to the Kabat scheme.
[0102] An "antibody that binds to the same or overlapping epitope as a reference antibody" is an antibody that blocks 50%, 60%, 70%, 80%, 90% or 95% or more of the binding of the reference antibody to its antigen in a competition assay, whereas conversely, the reference antibody blocks 50%, 60%, 70%, 80%, 90% or 95% or more of the binding of the antibody to its antigen in a competition assay.
[0103] An antibody that "competes for binding to its antigen" with a reference antibody is an antibody that blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the reference antibody to its antigen in a competition assay. Conversely, the reference antibody blocks 50%, 60%, 70%, 80%, 90%, or 95% or more of the binding of the antibody to its antigen in a competition assay. Numerous types of competitive binding assays can be used to determine whether one antibody competes with another, such as solid phase direct or indirect radioimmunoassays (RIAs), solid phase direct or indirect enzyme immunoassays (EIAs), and sandwich competition assays.
[0104] An "antibody that inhibits (e.g., competitively inhibits) the binding of a reference antibody to its antigen" refers to an antibody that inhibits the binding of the reference antibody to its antigen by 50%, 60%, 70%, 80%, 90%, or 95% or more. Conversely, the reference antibody inhibits the binding of the antibody to its antigen by 50%, 60%, 70%, 80%, 90%, or 95% or more. The binding of an antibody to its antigen can be measured by affinity (e.g., equilibrium dissociation constant). Methods for determining affinity are known in the art.
[0105] An "antibody that exhibits the same or similar binding affinity and / or specificity as a reference antibody" refers to an antibody that has at least 50%, 60%, 70%, 80%, 90% or more of the binding affinity and / or specificity of the reference antibody. This can be determined by any method known in the art for determining binding affinity and / or specificity.
[0106] The term "chimeric antibody" is an antibody molecule in which (a) the constant region or a portion thereof is changed, replaced or exchanged so that the antigen binding site is connected to a constant region of a different or altered class, effector function and / or species or a completely different molecule (e.g., enzyme, toxin, hormone, growth factor, drug) that imparts new properties to the chimeric antibody; or (b) the variable region or a portion thereof is changed, replaced or exchanged with a variable region having a different or altered antigenic specificity. For example, a mouse antibody can be modified by replacing its constant region with a constant region from a human immunoglobulin. Due to the replacement with a human constant region, the chimeric antibody can retain its specificity in recognizing the antigen while having reduced immunogenicity in humans as compared to the original mouse antibody.
[0107] A "humanized antibody" is an antibody that retains the antigen-specific reactivity of a non-human antibody (e.g., a mouse monoclonal antibody) while being less immunogenic when administered to humans as a therapeutic agent. This can be achieved, for example, by retaining the non-human antigen-binding site and replacing the remaining portions of the antibody with their human counterparts (e.g., replacing the constant region and portions of the variable region not involved in binding with the corresponding portions of a human antibody).
[0108] The term "Fc domain" or "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. A native immunoglobulin "Fc domain" comprises two or three constant domains, namely a CH2 domain, a CH3 domain, and an optional CH4 domain. For example, in a native antibody, an immunoglobulin Fc domain comprises the second and third constant domains (CH2 domain and CH3 domain) of two heavy chains derived from IgG, IgA, and IgD class antibodies; or the second, third, and fourth constant domains (CH2 domain, CH3 domain, and CH4 domain) of two heavy chains derived from IgM and IgE class antibodies. Unless otherwise indicated herein, the amino acid residues in the Fc region or heavy chain constant region are numbered according to the EU numbering system (also referred to as the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interes, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991, NIH Publication 91-3242. However, the C-terminal lysine (Lys447) in the Fc region may or may not be present. Two Fc regions may dimerize to form a dimeric Fc, and two different Fc regions may heterodimerize to form a heterodimeric Fc. As used herein, the terms "Fc region," "Fc portion," and "dimeric Fc" do not include the heavy chain variable region VH and light chain variable region VL, as well as the heavy chain constant region CH1 and light chain constant region CL of an immunoglobulin, but in some cases may include the hinge region or a portion of the hinge region at the N-terminus of the heavy chain constant region, for example, the IgG1 hinge region or a portion of the IgG1 hinge region, for example, the sequence from D221 to P230 according to EU numbering. In one embodiment, the human IgG heavy chain Fc region extends from Asp221, or from Cys226, or from Asp231 to the carboxyl terminus of the heavy chain.
[0109] In one embodiment, the human IgG1 Fc region polypeptide (including the hinge region) comprises the following amino acid sequence:
[0110] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:23 The underlined area is the hinge area).
[0111] The term "effector function" refers to the functional ability of the Fc or constant region of an antibody to bind proteins and / or cells of the immune system.
[0112] The terms "amino acid substitution" or "amino acid replacement" are used interchangeably herein and refer to the replacement of at least one amino acid residue in a predetermined parent amino acid sequence with a different "replacement" amino acid residue. The replacement residue or residues can be "naturally occurring amino acid residues" (i.e., encoded by the genetic code) and are selected from the group consisting of: alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gln); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (Ile); leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val). Also encompassed within the definition of amino acid substitution herein is replacement with one or more non-naturally occurring amino acid residues. "Non-natural amino acid residues" refer to residues that are capable of covalently binding to adjacent amino acid residues in a polypeptide chain, in addition to those naturally occurring amino acid residues listed above. Examples of non-natural amino acid residues include norleucine, ornithine, norvaline, homoserine, Aib and other amino acid residue analogs.
[0113] In some embodiments, amino acid substitutions are represented by (original amino acid, amino acid position, mutated amino acid). For example, when the substitution site is in region C, "L234A" means that the leucine (L) at EU position 234 is replaced by alanine (A). When referring to a combination of mutations, the combined mutations are separated by a slash. "L234A / L235A" indicates that both the L234A and L235A mutations are present.
[0114] In some embodiments, an amino acid deletion is represented by Δ+amino acid+mutation site, for example, ΔP329 represents a deletion of proline at position 329. An amino acid deletion can also be represented by "amino acid+mutation site+deletion", for example, a deletion of proline at position 329 can also be written as "P329 deletion".
[0115] As used herein, "conservative changes" include substitutions, deletions, or additions to a polypeptide sequence that do not substantially alter the desired functional activity of the polypeptide sequence. In some embodiments, conservative changes are conservative substitutions. A conservative substitution refers to the replacement of one amino acid with another within the same class, such as the replacement of an acidic amino acid with another acidic amino acid, the replacement of a basic amino acid with another basic amino acid, or the replacement of a neutral amino acid with another neutral amino acid. For example, conservative substitutions often result in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following lists 8 groups of amino acids containing conservative substitutions for each other: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M). In some embodiments, the term "conservative change" when applied to an antibody molecule amino acid sequence refers to an amino acid modification that does not significantly affect or change the target antigen binding characteristics of the antibody molecule of the present invention containing the amino acid sequence. For example, a conservatively changed variant maintains at least 80%, 85%, 90%, 95%, 98%, 99% or higher, such as 100-110% or higher, binding affinity for the target antigen relative to the parent antibody.
[0116] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."
[0117] An "immunoconjugate" is an antibody conjugated to one or more additional substances, including but not limited to a label.
[0118] The term "therapeutic agent" as used herein encompasses any active agent effective in preventing or treating diseases associated with inappropriate activation of CD40L / CD40-mediated pathways, for example, an active agent that produces a biological effect. Active agents that produce a biological effect include, but are not limited to, cytokines, other antibodies, small molecule drugs, or immunomodulators (e.g., immunosuppressants).
[0119] The term "small molecule drug" refers to low molecular weight organic compounds that are capable of regulating biological processes. "Small molecules" are defined as molecules with a molecular weight of less than 10 kD, typically less than 2 kD, and preferably less than 10 kD. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing inorganic components, molecules containing radioactive atoms, synthetic molecules, peptide mimetics, and antibody mimics. As therapeutic agents, small molecules can be more cell-permeable, less susceptible to degradation, and less prone to eliciting an immune response than macromolecules.
[0120] As used herein, the term "immunomodulator" refers to a natural or synthetic agent or drug that inhibits or modulates an immune response. The immune response can be a humoral response or a cellular response. Immunomodulators include immunosuppressants.
[0121] As used herein, an "immunosuppressant," "immunosuppressive drug," or "immunosuppressant" is a therapeutic agent used in immunosuppressive therapy to suppress or prevent the activity of the immune system.
[0122] The term "effective amount" refers to an amount or dosage of an antibody or fragment or conjugate or composition or combination of the present invention that produces the desired effect in a patient in need of treatment or prevention after administration in single or multiple doses to the patient.
[0123] "Therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the required dosage and for the required period of time. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or its conjugate or composition or combination are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor volume) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70% relative to an untreated subject. In some embodiments, the term "therapeutically effective amount" as used herein is intended to define the amount of therapy necessary to treat a condition (e.g., autoimmunity, allergy, inflammation, GVHD, or transplantation) or to reduce or eliminate an immune response, particularly a T cell or B cell antibody response to an antigen (e.g., an autoantigen, an allergen, an inflammatory inducer, a transplanted cell, tissue, or organ) or an antagonist (e.g., a biological, e.g., therapeutic antibody, Ig fusion protein, hormone, growth factor, or other therapeutic protein or polypeptide) in a therapeutic regimen.
[0124] A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result at the required dosage and for the required period of time. Typically, a prophylactic dose will be less than a therapeutically effective amount because prophylactic doses are used in subjects before or at an earlier stage of the disease. In some embodiments, the term "prophylactically effective amount" as used herein is intended to define the amount of treatment necessary to prevent the progression and symptoms of a condition or disease (e.g., autoimmune, allergic, inflammatory, GVHD or anti-transplant, drug or rejection reactions) in a treatment regimen.
[0125] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to the parent cell, but may contain mutations. Mutant progeny screened or selected for the same function or biological activity as the initially transformed cell are included herein.
[0126] The term "label" as used herein refers to a compound or composition that is directly or indirectly conjugated or fused to a reagent (such as a polynucleotide probe or antibody) and promotes the detection of the reagent to which it is conjugated or fused. The label itself can be detectable (e.g., a radioisotope label or a fluorescent label) or can catalyze a chemical change in a detectable substrate compound or composition in the case of an enzymatic label. The term is intended to encompass direct labeling of a probe or antibody by coupling (i.e., physically connecting) a detectable substance to the probe or antibody and indirect labeling of the probe or antibody by reacting with another reagent of the direct label.
[0127] "Individual," "object," or "subject" includes mammals. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.
[0128] "Subject / patient / individual sample" refers to a collection of cells or fluids obtained from a patient or subject. The source of a tissue or cell sample can be solid tissue, such as an organ or tissue sample or a biopsy sample or a puncture sample from a fresh, frozen and / or preserved organ; blood or any blood component; body fluids, such as cerebrospinal fluid, amniotic fluid (amniotic fluid), peritoneal fluid (ascites), or interstitial fluid; cells from any time during the subject's pregnancy or development. Tissue samples may contain compounds that are not naturally contaminated with tissue in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc.
[0129] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC).
[0130] "Isolated nucleic acid encoding an anti-CD40L antibody or fragment thereof" refers to one or more nucleic acid molecules that encode an antibody heavy chain or light chain (or fragment thereof, such as a heavy chain variable region or a light chain variable region), including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present at one or more locations in a host cell.
[0131] "Percent identity (%)" of an amino acid sequence refers to the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the specific amino acid sequence set forth in this specification, after aligning the candidate sequence with the specific amino acid sequence set forth in this specification and introducing gaps, if necessary, to achieve the maximum percentage identity, and not considering any conservative substitutions as part of the sequence identity. In some embodiments, the present invention contemplates variants of the antibody molecules of the present invention that have a substantial degree of identity, e.g., at least 80%, 85%, 90%, 95%, 97%, 98% or 99% or more, relative to the antibody molecules and sequences thereof specifically disclosed herein. Such variants may comprise conservative changes.
[0132] The term "pharmaceutical excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, carrier, stabilizer, or the like, which is administered together with the active substance.
[0133] The term "pharmaceutical composition" refers to a composition that is in form permitting the biological activity of the active ingredient contained therein to be effective, and that contains no additional ingredients that are unacceptably toxic to a subject to which the composition would be administered.
[0134] The term "pharmaceutical combination" refers to a non-fixed combination product or a fixed combination product, including but not limited to a kit and a pharmaceutical composition. The term "non-fixed combination" means that the active ingredients (e.g., (i) an anti-CD40L antibody or fragment thereof, and (ii) an additional therapeutic agent) are administered to a patient as separate entities simultaneously, without specific time limits, or sequentially at equal or different time intervals, wherein such administration provides prophylactically or therapeutically effective levels of the two or more active agents in the patient. In some embodiments, the anti-CD40L antibody or fragment thereof and the additional therapeutic agent used in the pharmaceutical combination are administered at levels no greater than when they are administered alone. The term "fixed combination" means that the two or more active agents are administered to a patient simultaneously as a single entity. The dosages and / or time intervals of the two or more active agents are preferably selected so that the combined use of the components produces an effect greater than that achieved by either component alone in treating a disease or condition. Each component may be in a separate formulation, which may be the same or different.
[0135] The term "combination therapy" refers to the administration of two or more therapeutic agents or treatment modalities (e.g., radiotherapy or surgery) to treat diseases described herein. This administration includes co-administering these therapeutic agents in a substantially simultaneous manner, such as in a single capsule with a fixed ratio of active ingredients. Alternatively, this administration includes co-administration of each active ingredient in a variety of or separate containers (e.g., tablets, capsules, powders, and liquids). Powders and / or liquids can be reconstituted or diluted to the desired dose before administration. In addition, this administration also includes using each type of therapeutic agent in a sequential manner at approximately the same time or at different times. In either case, the therapeutic regimen will provide the beneficial effects of the drug combination in treating disorders or conditions described herein.
[0136] As used herein, "treat," ...
[0137] As used herein, "prevention" includes the inhibition of the onset or development of a disease or condition or symptoms of a particular disease or condition.
[0138] All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference in their entirety. Any or all features discussed above and throughout this application can be combined in various embodiments of the present invention. In addition, the materials, methods and examples described herein are only illustrative and are not intended to be restrictive. Other features, purposes and advantages of the present invention will become apparent from this specification and accompanying drawings and from the appended claims.
[0139] II Antibodies
[0140] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention bind to CD40L (e.g., human CD40L) with high affinity. In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention bind to human CD40L with higher affinity than known CD40L antibodies, such as the INX-021 antibody (WO2017011544A1).
[0141] In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention bind to CD40L on the surface of a cell. In some embodiments, CD40L is expressed or overexpressed on the surface of a cell. In some embodiments, the cell is a CHO cell that expresses or overexpresses CD40L.
[0142] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention have one or more of the following properties:
[0143] a) binds to CD40L (e.g., human CD40L) with high affinity;
[0144] b) Inhibit the binding of CD40 to CD40L
[0145] c) inhibiting the CD40 / CD40L signaling pathway;
[0146] d) inhibit B cell activation;
[0147] e) inhibiting the proliferation of B cells;
[0148] f) inhibiting B cell maturation and differentiation, such as inhibiting B cell differentiation into plasma cells;
[0149] g) inhibiting the secretion of IL-12 by dendritic cells;
[0150] h) does not cause platelet activation (e.g., in vitro or in vivo);
[0151] i) Treatment or prevention of immune diseases, such as multiple sclerosis (MS);
[0152] j) suppressing an immune response, preferably a humoral immune response, such as suppressing the production of antibodies; and / or
[0153] k) improved pharmacokinetics, preferably having an in vivo half-life equal to or greater than about 200 hours, more preferably equal to or greater than about 210, 220, 230, 240, 250, 260, 270, 280, or 290 hours.
[0154] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the invention comprise three complementarity determining regions (HCDRs) from the heavy chain variable region, HCDR1, HCDR2, and HCDR3.
[0155] In some embodiments, an anti-CD40L antibody or antigen-binding fragment thereof of the invention comprises three complementarity determining regions (LCDRs) from the light chain variable region, LCDR1, LCDR2, and LCDR3.
[0156] In some embodiments, an anti-CD40L antibody or antigen-binding fragment thereof of the invention comprises three complementarity determining regions (HCDRs) from a heavy chain variable region and three complementarity determining regions (LCDRs) from a light chain variable region.
[0157] In some aspects, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention comprise a heavy chain variable region (VH). In some aspects, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention comprise a light chain variable region (VH). In some aspects, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention comprise a heavy chain variable region and a light chain variable region (VH). In some embodiments, the heavy chain variable region comprises three complementary determining regions (CDRs) from the heavy chain variable region, HCDR1, HCDR2, and HCDR3. In some embodiments, the light chain variable region comprises three complementary determining regions (CDRs) from the light chain variable region, LCDR1, LCDR2, and LCDR3.
[0158] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody heavy chain constant region HC. In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody light chain constant region LC. In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise a heavy chain constant region HC and a light chain constant region LC.
[0159] In some embodiments, the heavy chain variable region of the present invention:
[0160] (i) comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from any one of SEQ ID NO: 4 and SEQ ID NO: 16; or
[0161] (ii) comprises or consists of an amino acid sequence selected from any one of SEQ ID NO: 4 and SEQ ID NO: 16; or
[0162] (iii) an amino acid sequence comprising one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to the amino acid sequence selected from any one of SEQ ID NO: 4 and SEQ ID NO: 16, consisting of said amino acid sequence. Preferably, said amino acid changes do not occur in the CDR regions.
[0163] In some embodiments, the light chain variable region of the present invention
[0164] (i) comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from any one of SEQ ID NO: 10 and SEQ ID NO: 21; or
[0165] (ii) comprises or consists of an amino acid sequence selected from any one of SEQ ID NO: 10 and SEQ ID NO: 21; or
[0166] (iii) an amino acid sequence comprising one or more (preferably no more than 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to the amino acid sequence selected from any one of SEQ ID NO: 10 and SEQ ID NO: 21, consisting of said amino acid sequence. Preferably, said amino acid changes do not occur in the CDR regions.
[0167] In some embodiments, the three complementarity determining regions (HCDRs) of the present invention, HCDR1, HCDR2, and HCDR3, from the heavy chain variable region are selected from
[0168] (i) three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH as shown in SEQ ID NO: 4 or 16;
[0169] (ii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid change (preferably an amino acid substitution, preferably a conservative substitution) in the three HCDR regions relative to the sequence of any one of (i),
[0170] For example, wherein the HCDRs can be determined according to any scheme for determining CDRs, such as according to the Kabat, AbM, Chothia, Contact or IMGT schemes, respectively, or a combination thereof;
[0171] For example, the HCDR1 is determined according to the combined Kabat and Chothia scheme, and the HCDR2 and HCDR3 are determined according to the Kabat scheme.
[0172] In some embodiments, the three complementarity determining regions (LCDRs) of the present invention, LCDR1, LCDR2, and LCDR3, from the light chain variable region are selected from
[0173] (i) three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL as shown in SEQ ID NO: 10 or 21, or
[0174] (ii) a sequence comprising at least one and no more than 5, 4, 3, 2 or 1 amino acid change (preferably an amino acid substitution, preferably a conservative substitution) in the three LCDR regions relative to the sequence of any one of (i),
[0175] For example, wherein the LCDR can be determined according to any scheme for determining CDRs, such as according to the Kabat, AbM, Chothia, Contact or IMGT schemes, respectively, or a combination thereof;
[0176] For example, the LCDR1-3 are determined according to the Kabat protocol.
[0177] In some embodiments, HCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 1 or 13, or HCDR1 comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 1 or 13.
[0178] In some embodiments, HCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 2 or 14, or HCDR2 comprises an amino acid sequence having one, two or three alterations (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 2 or 14.
[0179] In some embodiments, HCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 3 or 15, or HCDR3 comprises an amino acid sequence having one, two or three alterations (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 3 or 15.
[0180] In some embodiments, LCDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 7 or 18, or LCDR1 comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 7 or 18.
[0181] In some embodiments, LCDR2 comprises or consists of the amino acid sequence of SEQ ID NO: 8 or 19, or LCDR2 comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 8 or 19.
[0182] In some embodiments, LCDR3 comprises or consists of the amino acid sequence of SEQ ID NO: 9 or 20, or LCDR3 comprises an amino acid sequence having one, two or three changes (preferably amino acid substitutions, preferably conservative substitutions) compared to the amino acid sequence of SEQ ID NO: 9 or 20.
[0183] In some embodiments, the heavy chain constant region of the antibody of the present invention is the heavy chain constant region of IgG1, IgG2, IgG3 or IgG4, preferably the heavy chain constant region of IgG1. In some embodiments, the light chain constant region of the antibody of the present invention is the lambda or kappa light chain constant region, preferably the kappa light chain constant region.
[0184] In some embodiments, the heavy chain constant region of an antibody of the invention comprises a mutated Fc region.
[0185] Therefore, the present invention also relates to a mutated Fc region.
[0186] In some embodiments, the Fc region is an IgG Fc from a human, e.g., an Fc from a human IgG1, an Fc from a human IgG2, an Fc from a human IgG3, or an Fc from a human IgG4. In one embodiment, the Fc region comprises or consists of the amino acid sequence of SEQ ID NO: 23 or 24, or an amino acid sequence having at least 90% identity thereto, e.g., 95%, 96%, 97%, 99% or more identity thereto.
[0187] In one embodiment, the Fc region is modified with respect to the properties of the effector function of the Fc region (e.g., the complement activation function of the Fc region). In one embodiment, the effector function has been reduced or eliminated relative to a wild-type Fc region. In one embodiment, the effector function is reduced or eliminated by a method selected from the group consisting of: using an Fc isotype that naturally has reduced or eliminated effector function, and Fc region modification.
[0188] In a preferred embodiment, the Fc region has reduced effector function mediated by the Fc region, such as reduced or abolished ADCC or ADCP or CDC effector function, eg, comprises a mutation that achieves the above function.
[0189] The Fc region may include modifications that alter binding affinity for one or more Fc receptors. In one embodiment, the Fc receptor is an Fcγ receptor, particularly a human Fcγ receptor. In some embodiments, the Fc region includes mutations that reduce binding to Fcγ receptors. For example, in some embodiments, the Fc region used in the present invention has L234A / L235A mutations that reduce binding to Fcγ receptors. In another preferred embodiment, the Fc fragment may have mutations that result in increased serum half-life, such as mutations that improve binding of the Fc fragment to FcRn.
[0190] In a preferred embodiment, the Fc region of the present invention has reduced binding to FcγRs (preferably completely abolished binding to all FcγRs) while still retaining affinity for FcRn. Therefore, the Fc region used in the present invention has L234A / L235A and P329 deletion mutations.
[0191] Therefore, in a preferred embodiment, the Fc region of the present invention comprises the amino acid sequence of SEQ ID NO: 24, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 24 and has L234A / L235A and P329 deletion mutations.
[0192] In some preferred embodiments, the heavy chain constant region of the antibody of the present invention is
[0193] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 5 or 26;
[0194] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 5 or 26; or
[0195] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 5 or 26.
[0196] In some preferred embodiments, the heavy chain constant region of an antibody of the present invention comprises an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 5, and has L234A / L235A and P329 deletion mutations. In some preferred embodiments, the heavy chain constant region of an antibody of the present invention comprises or consists of an amino acid sequence selected from SEQ ID NO: 5.
[0197] In some embodiments, the antibody light chain constant region of the invention is
[0198] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 11;
[0199] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 11; or
[0200] (iii) comprises or consists of an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to the amino acid sequence selected from SEQ ID NO: 11.
[0201] In some specific embodiments, the anti-CD40L antibodies of the invention comprise a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), a third heavy chain complementarity determining region (HCDR3), and a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3), wherein:
[0202] (i) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise or consist of the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9; or
[0203] (ii) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or respectively consist of the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20.
[0204] In some embodiments, the VH of the present invention comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, and the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, or consist of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and the LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, or consist of the amino acid sequences shown in SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively.
[0205] In some embodiments, the VH of the present invention comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, and the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, or consist of the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, respectively, and the LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, or consist of the amino acid sequences shown in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, respectively.
[0206] In some embodiments, the antibodies or antigen-binding fragments thereof of the invention:
[0207] (i) a VH comprising, or consisting of, an amino acid sequence as set forth in SEQ ID NO: 4, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and / or a VL comprising, or consisting of, an amino acid sequence as set forth in SEQ ID NO: 10, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0208] (ii) a VH comprising, or consisting of, an amino acid sequence as set forth in SEQ ID NO: 16, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and / or a VL comprising, or consisting of, an amino acid sequence as set forth in SEQ ID NO: 21, or an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0209] In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention comprise a heavy chain variable region and a light chain variable region, wherein
[0210] (i) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 4, and the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 10; or
[0211] (ii) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 16, and the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 21.
[0212] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody heavy chain. In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise an antibody light chain. In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention further comprise a heavy chain and a light chain. In some embodiments, the heavy chain of the antibodies of the present invention comprises a heavy chain variable region and a heavy chain constant region, or consists of a heavy chain variable region and a heavy chain constant region. In some embodiments, the light chain of the antibodies of the present invention comprises a light chain variable region and a light chain constant region, or consists of a light chain variable region and a light chain constant region. In some embodiments, the antibodies of the present invention comprise two heavy chains and two light chains, or consist of two heavy chains and two light chains.
[0213] In some embodiments, an antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain, wherein the heavy chain
[0214] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 6 or 17;
[0215] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 6 or 17; or
[0216] (iii) comprises an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 6 or 17, or consists of said amino acid sequence.
[0217] In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention comprise a light chain, wherein the light chain
[0218] (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 12 or 22;
[0219] (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 12 or 22; or
[0220] (iii) comprising an amino acid sequence having one or more (preferably no more than 20 or 10, more preferably no more than 5, 4, 3, 2, or 1) amino acid changes (preferably amino acid substitutions, more preferably conservative amino acid substitutions) compared to an amino acid sequence selected from SEQ ID NO: 12 or 22, or consisting of said amino acid sequence. In some embodiments, the antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein
[0221] (i) the heavy chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 6; and / or the light chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12;
[0222] (ii) the heavy chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 17; and / or the light chain comprises, or consists of, an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 22.
[0223] In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention comprise a heavy chain and a light chain, wherein
[0224] (i) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 6, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 12; or
[0225] (ii) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 17, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 22.
[0226] In one embodiment of the present invention, the amino acid changes described herein include amino acid substitutions, insertions or deletions. Preferably, the amino acid changes described herein are amino acid substitutions, preferably conservative substitutions.
[0227] In a preferred embodiment, the amino acid changes described herein occur in regions outside of the CDRs (e.g., in the FRs). More preferably, the amino acid changes described herein occur in regions outside of the heavy chain variable region and / or outside of the light chain variable region.
[0228] In certain embodiments, the antibodies provided herein are modified to increase or decrease the degree of glycosylation of the antibody. Addition or deletion of the glycosylation site of the antibody can be easily achieved by changing the amino acid sequence to produce or remove one or more glycosylation sites. When the antibody comprises an Fc region, the carbohydrate attached thereto can be changed. In some applications, it can be useful to remove the modification of unwanted glycosylation sites, for example, removing the fucose motif to improve antibody-dependent cellular toxicity (ADCC) function. In other applications, galactosidation can be performed to modify complement-dependent cytotoxicity (CDC).
[0229] In certain embodiments, it may be desirable to generate cysteine engineered antibodies, eg, "thioMAbs," in which one or more residues of an antibody are substituted with cysteine residues.
[0230] In certain embodiments, the antibodies provided herein may be further modified to contain other non-proteinaceous moieties known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
[0231] In some embodiments, the anti-CD40L antibodies or antigen-binding fragments thereof of the present invention have one or more of the following properties:
[0232] (i) exhibiting the same or similar binding affinity and / or specificity for CD40L as the antibodies of the present invention;
[0233] (ii) inhibiting (e.g., competitively inhibiting) the binding of an antibody of the invention to CD40L;
[0234] (iii) binds to the same or overlapping epitope as an antibody of the invention;
[0235] (iv) competing with the antibodies of the present invention for binding to CD40L;
[0236] (v) possess one or more biological properties of an antibody of the invention.
[0237] In some embodiments, the anti-CD40L antibody of the present invention is an antibody in the form of IgG1, an antibody in the form of IgG2, an antibody in the form of IgG3, or an antibody in the form of IgG4, preferably, an antibody in the form of IgG1.
[0238] In some embodiments, the anti-CD40L antibody is a monoclonal antibody.
[0239] In some embodiments, the anti-CD40L antibody is humanized.
[0240] In some embodiments, the anti-CD40L antibody is a chimeric antibody.
[0241] In one embodiment, the anti-CD40L antibodies of the present invention also encompass antibody fragments thereof (e.g., antigen-binding fragments), preferably antibody fragments selected from the group consisting of: Fv, Fab, Fab', Fab'-SH, F(ab')2, dAb (domain antibody), linear antibodies, single-chain antibodies (e.g., scFv); single-domain antibodies (sdAb) such as VHH, diabodies or fragments thereof, or camelid antibodies or diabodies.
[0242] In some embodiments, the anti-CD40L antibodies of the present invention also encompass multispecific antibodies, such as bispecific antibodies, that specifically bind to CD40L.
[0243] In some embodiments, the anti-CD40L antibodies of the invention are full-length antibodies.
[0244] III. Nucleic acids of the present invention and host cells containing the same
[0245] In one aspect, the present invention provides nucleic acids encoding any chain, monomer, or domain of an antibody or antigen-binding fragment thereof of the present invention. Polynucleotide sequences encoding each chain can be generated using methods well known in the art. For example, when expressed from a suitable expression vector, the polypeptide encoded by the nucleic acid can exhibit human CD40L antigen binding ability. For example, in some embodiments, the nucleic acid encoding the variable region of the heavy chain and / or light chain is operably linked in frame with the nucleic acid encoding the constant region of the heavy chain and / or light chain, thereby generating a nucleic acid encoding the heavy chain and / or light chain of the antibody when expressed from a suitable expression vector.
[0246] In one aspect, the present invention provides nucleic acids encoding any of the anti-CD40L antibodies or fragments thereof described herein. The nucleic acids may comprise nucleic acids encoding the amino acid sequences of the light chain variable region and / or heavy chain variable region of the antibody, or nucleic acids encoding the amino acid sequences of the light chain and / or heavy chain of the antibody.
[0247] For example, nucleic acids of the invention include nucleic acids encoding an amino acid sequence selected from any one of SEQ ID NOs: 4-6, 10, 12, 16, 17, 21, and 22, or nucleic acids encoding an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from any one of SEQ ID NOs: 4-6, 10, 12, 16, 17, 21, and 22. As will be apparent to those skilled in the art, due to codon degeneracy, each antibody or polypeptide amino acid sequence can be encoded by multiple nucleic acid sequences. In some embodiments, the nucleic acid of the invention comprises a nucleic acid selected from any one of SEQ ID NOs: 28-31, or a nucleic acid that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a nucleic acid selected from any one of SEQ ID NOs: 28-31.
[0248] Nucleic acid sequences encoding molecules of the present invention can be generated using methods well known in the art, such as de novo solid phase DNA synthesis or PCR amplification.
[0249] To facilitate production and purification, a secretory signal peptide and / or a tag peptide that facilitates purification can be fused to the N-terminus of the heavy chain and / or light chain of the antibody.
[0250] The present invention also provides vectors comprising nucleic acids of the present invention. In one embodiment, the vector is an expression vector, such as a eukaryotic expression vector. Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YACs). In preferred embodiments, the expression vector of the present invention is a pcDNA vector, such as the pcDNA3.1 expression vector.
[0251] In one embodiment, a host cell comprising the vector is provided. The present invention also provides a host cell comprising the nucleic acid or the vector. Host cells suitable for replication and support expression of the antibodies of the present invention are well known in the art. Such cells can be transfected or transduced with specific expression vectors, and large quantities of vector-containing cells can be grown for inoculating large-scale fermenters, thereby obtaining sufficient amounts of antibodies for clinical applications. Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required. After expression, the antibodies can be separated from the bacterial cell paste in the soluble fraction and can be further purified.
[0252] In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells (e.g., CHO-K1, CHO-S, CHO-K or ExpiCHO cells) or 293 cells (e.g., 293F or HEK293 cells)) or other cells suitable for preparing antibodies or fragments thereof. In one embodiment, the host cell is prokaryotic, for example, a bacterium, such as Escherichia coli.
[0253] For example, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors. For example, fungal and yeast strains whose glycosylation pathways have been "humanized" result in the production of antibodies with partially or fully human glycosylation patterns. Host cells suitable for expressing glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Vertebrate cells can also be used as hosts. For example, mammalian cell lines modified to be suitable for suspension growth can be used. Other examples of useful mammalian host cell lines are monkey kidney CV1 line (COS-7) transformed with SV40; human embryonic kidney lines (HEK293, 293F or 293T cells), etc. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including CHO-K1, CHO-K, DHFR-CHO cells, CHO-S cells, ExpiCHO, etc.; and myeloma cell lines such as Y0, NS0 and Sp2 / 0. Mammalian host cell lines suitable for producing antibodies are known in the art.
[0254] V. Production and Purification of Antibody Molecules of the Invention
[0255] In one embodiment, the present invention provides a method for preparing an antibody molecule or fragment thereof (preferably an antigen-binding fragment) of the present invention, wherein the method comprises culturing the host cell under conditions suitable for expressing a nucleic acid encoding an antibody molecule or fragment thereof (preferably an antigen-binding fragment) of the present invention, and optionally isolating the antibody or fragment thereof (e.g., an antigen-binding fragment). In a certain embodiment, the method further comprises recovering the antibody molecule or fragment thereof (e.g., an antigen-binding fragment) of the present invention from the host cell.
[0256] The polynucleotide encoding the polypeptide chain of the antibody of the present invention can be inserted into one or more vectors for further cloning and / or expression in a host cell. Methods well known to those skilled in the art can be used to construct expression vectors. Once an expression vector comprising one or more nucleic acid molecules of the present invention has been prepared for expression, the expression vector can be transfected or introduced into a suitable host cell. A variety of techniques can be used to achieve this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, liposome-based transfection or other conventional techniques.
[0257] The antibody molecules prepared as described herein can be purified by known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, hydrophilicity, and such factors, and these will be apparent to those skilled in the art. The purity of the antibody molecules of the invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.
[0258] VI. Assay
[0259] The anti-CD40L antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.
[0260] The present invention also provides assays for identifying anti-CD40L antibodies with biological activity. Biological activities can include, for example, binding to CD40L (e.g., binding to human CD40L), inhibition of the CD40 / CD40L signaling pathway, blocking the binding of CD40 to CD40L, inhibition of B cell activation, inhibition of B cell proliferation, inhibition of B cell differentiation, inhibition of cytokine secretion by dendritic cells, inhibition of antibody production in a subject, and therapeutic effects on immune system diseases. Antibodies with such biological activities in vivo and / or in vitro are also provided.
[0261] For the determination of the above biological activity, please refer to the exemplary determination methods given in the Examples.
[0262] It will be appreciated that any of the above assays can be performed using the immunoconjugates of the invention in place of or in addition to the anti-CD40L antibody.
[0263] It will be appreciated that any of the above assays can be performed using a combination of anti-CD40L antibodies and additional active agents.
[0264] VII. Immunoconjugates
[0265] In some embodiments, the present invention provides immunoconjugates comprising any of the anti-CD40L antibodies provided herein and other substances, such as therapeutic agents or labels. In some embodiments, the therapeutic agent can be a therapeutic agent suitable for forming an immunoconjugate with the CD40L antibody, for example, an active agent or active ingredient that produces a biological effect. Active agents that produce a biological effect include, but are not limited to, cytokines, other antibodies, small molecule drugs, or immunomodulators (e.g., immunosuppressants).
[0266] In some embodiments, the immunoconjugate is an antibody drug conjugate (ADC).
[0267] VIII. Pharmaceutical Compositions and Pharmaceutical Formulations
[0268] In some embodiments, the present invention provides a composition comprising any of the anti-CD40L antibodies or fragments thereof (preferably antigen-binding fragments thereof) or immunoconjugates thereof described herein, preferably a pharmaceutical composition. In one embodiment, the composition further comprises a pharmaceutical excipient. In one embodiment, the composition, e.g., a pharmaceutical composition, comprises an anti-CD40L antibody or fragment thereof or immunoconjugate thereof of the present invention in combination with one or more other therapeutic agents.
[0269] The present invention also encompasses compositions (including pharmaceutical compositions or pharmaceutical preparations) comprising anti-CD40L antibodies or immunoconjugates thereof, or compositions (including pharmaceutical compositions or pharmaceutical preparations) comprising polynucleotides encoding anti-CD40L antibodies. In certain embodiments, the compositions comprise one or more antibodies or fragments thereof that bind to CD40L, or one or more polynucleotides encoding one or more anti-CD40L antibodies or fragments thereof. These compositions may also contain suitable pharmaceutical excipients, such as pharmaceutical carriers and excipients known in the art, including buffers.
[0270] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.
[0271] For the use of pharmaceutical excipients and their applications, see also "Handbook of Pharmaceutical Excipients", 8th edition, RC Rowe, PJ Eskey and S C Owen, Pharmaceutical Press, London, Chicago.
[0272] The compositions of the present invention can be in a variety of forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusible solutions), powders or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic use.
[0273] Pharmaceutical formulations comprising the antibodies described herein can be prepared by mixing the antibodies of the invention having the desired degree of purity with one or more optional pharmaceutical excipients, preferably in the form of a lyophilized formulation or an aqueous solution.
[0274] The pharmaceutical compositions or formulations of the present invention may also contain more than one active ingredient, the active ingredients being required for the specific indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it is desirable to also provide other therapeutic agents, such as active agents that produce biological effects in the prevention or treatment of diseases associated with inappropriate activation of CD40L / CD40-mediated pathways, including but not limited to cytokines, small molecule drugs, immunomodulators (e.g., immunosuppressants), or other antibodies. The active ingredients are suitably combined in amounts effective for the intended use. Sustained-release formulations can be prepared. Suitable examples of sustained-release formulations include semipermeable matrices of solid hydrophobic polymers containing antibodies, the matrix being in the form of shaped articles, such as films or microcapsules.
[0275] IX. Drug Combinations and Kits
[0276] In some embodiments, the present invention also provides a pharmaceutical combination or pharmaceutical combination product comprising an anti-CD40L antibody or fragment thereof (preferably an antigen-binding fragment) of the present invention, or an immunoconjugate thereof, and one or more other therapeutic agents (cytokines, small molecule drugs, immunomodulators (e.g., immunosuppressants or anti-inflammatory agents) or other antibodies, etc.).
[0277] Another object of the present invention is to provide a kit comprising the pharmaceutical combination of the present invention, preferably in the form of a pharmaceutical dosage unit, whereby dosage units can be provided according to a dosing regimen or a drug administration interval.
[0278] In one embodiment, the kit of parts of the present invention comprises in the same package:
[0279] - a first container containing a pharmaceutical composition comprising an anti-CD40L antibody or fragment thereof;
[0280] - A second container containing a pharmaceutical composition comprising an additional therapeutic agent.
[0281] In some embodiments, the other therapeutic agent is an active agent that produces a biological effect in preventing or treating diseases associated with inappropriate activation of CD40L / CD40-mediated pathways, including but not limited to cytokines, small molecule drugs, immunomodulators (e.g., immunosuppressants) or other antibodies.
[0282] X. Use and Method
[0283] In some embodiments, the antibodies of the present invention are used as a single agent or in combination to prevent or treat a disease or condition associated with abnormal activation of a CD40L / CD40-mediated signaling pathway in an individual.
[0284] In some embodiments, the disease or condition is a disease or condition of an abnormal immune system. In some embodiments, a patient with the disease or condition has an overactive immune system mediated by CD40L / CD40 compared to a healthy individual. In some embodiments, a patient with the disease or condition has abnormal activation of a CD40L / CD40-mediated signaling pathway compared to a healthy individual. In some embodiments, a patient with the disease or condition has excessive production or deposition of anti-autoantibodies compared to a healthy individual. In some embodiments, a patient with the disease or condition has excessive activation of a CD40L / CD40-mediated signaling pathway and excessive production and deposition of anti-autoantibodies compared to a healthy individual.
[0285] In some embodiments, patients with the disease or disorder have increased expression of CD40L or CD40 on cells (e.g., activated T cells or other types of immune or non-immune cells, such as epithelial cells, monocytes, dendritic cells, fibroblasts, smooth muscle cells, endothelial cells, and platelets), e.g., compared to corresponding cells in healthy individuals.
[0286] In some embodiments, the disease or condition includes, but is not limited to, autoimmune diseases, lupus nephritis, immune thrombocytopenic purpura (ITP), transplant rejection, Crohn's disease, inflammatory bowel disease (IBD), colitis, asthma / allergy, atherosclerosis, myasthenia gravis, multiple sclerosis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, coronary heart disease, type 1 diabetes, amyotrophic lateral sclerosis (ALS), and immune responses to recombinant drug products, such as hemophilia Factor VII.
[0287] In some embodiments, the antibodies or antibody fragments or immunoconjugates or compositions or products of the invention delay the onset of a disorder and / or symptoms associated with the disorder.
[0288] In some embodiments, the present invention provides use of an anti-CD40L antibody or fragment thereof, or an immunoconjugate or composition comprising the same, of the present invention in the production or preparation of a medicament for use as described herein, such as for preventing or treating the relevant diseases or conditions mentioned herein.
[0289] In some embodiments, the methods of prevention or treatment described herein further comprise administering to the subject or individual an antibody molecule, pharmaceutical composition, or immunoconjugate disclosed herein in combination with one or more other therapies, such as therapeutic modalities and / or other therapeutic agents. In some embodiments, the anti-CD40L antibodies or fragments thereof (as well as immunoconjugates, compositions, pharmaceutical compositions, formulations, etc. comprising the same) can also be administered in combination with one or more other therapies, such as therapeutic modalities and / or other therapeutic agents, for the purposes described herein, e.g., for preventing and / or treating the relevant diseases or conditions mentioned herein.
[0290] In some embodiments, the therapeutic agent is selected from cytokines, small molecule drugs, immunomodulators (such as immunosuppressants or anti-inflammatory agents) or other antibodies, etc.
[0291] In some embodiments, the antibodies described herein can be combined with other antibodies for separate administration, e.g., each as a separate antibody, or when linked (e.g., as a bispecific or multispecific antibody molecule).
[0292] The combination therapies of the present invention encompass both combined administration (e.g., two or more therapeutic agents contained in the same formulation or separate formulations), and separate administration, in which case administration of the antibody or fragment thereof of the present invention can occur before, simultaneously with, and / or after administration of the additional therapeutic agent and / or agent. In some embodiments, the additional therapeutic agent is an active agent that produces a biological effect, such as in the prevention or treatment of a disease associated with inappropriate activation of a CD40L / CD40-mediated pathway, including but not limited to cytokines, small molecule drugs, immunomodulators (e.g., immunosuppressants), or other antibodies.
[0293] The antibodies or fragments thereof of the present invention (as well as immunoconjugates, compositions, pharmaceutical compositions, preparations, combination products, etc. comprising the same) can be administered by any suitable method, including parenteral administration and, if desired for local treatment, intralesional administration. Parenteral injection or infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous injection or infusion.
[0294] XI. Methods and Compositions for Diagnosis and Detection
[0295] In one aspect, the present invention also relates to methods for diagnosis and detection of the antibodies or antigen-binding fragments thereof of the present invention and compositions for diagnosis and detection comprising the same.
[0296] In certain embodiments, any of the anti-CD40L antibodies or fragments thereof (preferably antigen-binding fragments) provided herein can be used to detect the presence of CD40L in a biological sample.
[0297] The term "detection" as used herein includes quantitative or qualitative detection, and exemplary detection methods can involve immunohistochemistry, immunocytochemistry, flow cytometry (e.g., FACS), magnetic beads of antibody molecule complexes, ELISA assays, PCR-techniques (e.g., RT-PCR). In certain embodiments, the biological sample is blood, serum, or other liquid samples of biological origin. In certain embodiments, the biological sample comprises cells or tissues.
[0298] In one embodiment, an anti-CD40L antibody or fragment thereof is provided for use in a method of diagnosis or detection.
[0299] In another aspect, a method for detecting the presence of CD40L in a biological sample is provided. In certain embodiments, the method comprises detecting the presence of CD40L protein in the biological sample. In certain embodiments, the CD40L is human CD40L. In certain embodiments, the method comprises contacting the biological sample with an anti-CD40L antibody or fragment thereof as described herein under conditions permissive for binding of the anti-CD40L antibody or fragment thereof to CD40L, and detecting whether a complex forms between the anti-CD40L antibody or fragment thereof and CD40L. Formation of a complex indicates the presence of CD40L. The method can be an in vitro or in vivo method. In one embodiment, the anti-CD40L antibody or fragment thereof is used to select a subject suitable for treatment with the anti-CD40L antibody or fragment thereof, e.g., wherein CD40L is a biomarker used to select the subject.
[0300] In some embodiments, labeled anti-CD40L antibodies or fragments thereof are provided. Labels include, but are not limited to, directly detectable labels or moieties (e.g., fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels), as well as moieties that are indirectly detected, such as enzymes or ligands, e.g., via an enzymatic reaction or molecular interaction.
[0301] In some embodiments provided herein, the sample is obtained prior to treatment with an anti-CD40L antibody or fragment thereof. In some embodiments, the sample is obtained prior to treatment with another therapy. In some embodiments, the sample is obtained during treatment with another therapy, or after treatment with another therapy.
[0302] In some embodiments, CD40L is detected prior to treatment, eg, prior to initiation of treatment or prior to a treatment after a treatment interval.
[0303] In some embodiments, a method of treating a disease of the present invention is provided, comprising: testing a subject (e.g., a sample) (e.g., a subject sample) for the presence of CD40L, thereby determining a CD40L value, comparing the CD40L value to a control value, and if the CD40L value is greater than the control value, administering to the subject a therapeutically effective amount of an anti-CD40L antibody or fragment thereof (e.g., an anti-CD40L antibody or fragment thereof described herein), optionally in combination with one or more other therapies, thereby treating the disease.
[0304] These and other aspects and embodiments of the present invention are described in the accompanying drawings (a brief description of the drawings follows) and the following detailed description of the invention and are exemplified in the following examples. Any or all of the features discussed above and throughout this application may be combined in various embodiments of the present invention. The following examples further illustrate the present invention, however, it should be understood that the examples are described in an illustrative and non-limiting manner, and that various modifications may be made by those skilled in the art. Example
[0305] Example 1: Screening and humanization of anti-CD40L antibodies
[0306] Using hybridoma technology, mice were immunized with a human CD40L (Human CD40 Ligand / TNFSF5 Protein, His, Flag Tag, active trimer (MALS verified), Acro) fusion protein. The mice were sacrificed, spleens were removed, and digested to a single-cell suspension. The splenocytes were then hybridized with proliferative myeloma cells. Hybridomas expressing positive antibodies were isolated in a selective culture medium. Mouse antibodies capable of blocking the CD40-CD40L interaction were then screened using in vitro ELISA and flow cytometry.
[0307] Electrofusion dish preparation
[0308] Soak the electrofusion dish thoroughly with 70% ethanol and blow dry it in a clean bench for later use.
[0309] Isolation of spleen cells: The mice were killed by cervical dislocation, and the body surface was disinfected with 75% alcohol for 5 minutes. Then, the mice were placed on the mouse dissection board in the clean bench, in the left lateral position, and the limbs were fixed with a No. 7 needle. The abdominal cavity was opened aseptically to remove the spleen, and the spleen was washed with 1640 (containing 10% fetal bovine serum, 1% Glutamax) culture medium, and the surrounding connective tissue was carefully removed. The spleen was then transferred to another dish containing basal culture medium. Press the spleen with a curved needle, make a hole in the spleen with a small needle, and squeeze it with tweezers to fully release the spleen cells to make a spleen cell suspension. After the cell suspension was filtered through a 70μM cell sieve, it was washed once with 30ml 1640 (containing 10% fetal bovine serum, 1% Glutamax) culture medium and centrifuged at 1200rpm for 6 minutes.
[0310] Lyse red blood cells
[0311] Remove the supernatant and resuspend the cells in 10 ml of RBC lysis buffer (GIBCO). Then, add an additional 20 ml of RBC lysis buffer. Let the suspension rest for 5 minutes, then centrifuge at 1100 rpm for 6 minutes. Remove the supernatant and resuspend the cells in 10 ml of basal medium. Then, add an additional 30 ml of basal medium and centrifuge at 1100 rpm for 6 minutes. Remove the supernatant and resuspend the cells in 20 ml of 1640 medium (containing 10% fetal bovine serum and 1% Glutamax) and count.
[0312] Electrofusion
[0313] Resuspend mouse myeloma SP2 / 0 cells (ATCC) in 20 ml of 1640 medium (containing 10% fetal bovine serum and 1% Glutamax) and count. Mix SP2 / 0 and spleen cells after lysis of red blood cells in a ratio of 1:2 to 1:1 and centrifuge at 1000 rpm for 6 minutes. After removing the supernatant, resuspend the mixed cells in 10 ml of fusion buffer (BTXpress). Add 15 ml of fusion buffer, centrifuge at 1000 rpm for 5 minutes, and remove the supernatant. Repeat the above steps once, add an appropriate volume of fusion buffer to resuspend the cells, and adjust the mixed cell density to 1×10 7 Add 2 ml of the above cell suspension to each electrofusion dish for electrofusion.
[0314] Plating after electrofusion
[0315] The cells were placed in the electrofusion dish at room temperature for 5 minutes. The cells were transferred to a centrifuge tube and diluted to 1-2×10 cells with screening medium 1640 (containing 10% fetal bovine serum, 1% Glutamax, and 1% HAT medium). 4Cells / ml. Add 100 μl of cell suspension to each well of a 96-well plate. Change the selection medium on day 7 after fusion. After culture for 10 days (or longer depending on cell growth status), hybridoma cells expressing specific anti-CD40L antibodies can be screened using ELISA and flow cytometry.
[0316] Positive hybridoma cell subcloning
[0317] Prepare a 96-well plate and add 200 μl of the above-mentioned 1640 medium (containing 10% fetal bovine serum and 1% Glutamax) to each well of rows 2 to 8. Cells from the positive wells screened by the above fusion were plated at a rate of approximately 1×10 5 At a density of cells / ml, take 300ul and add it to each well in the first row. Using a strainer, take 100μl of the cell suspension from the first row and add it to the second row. Mix thoroughly and then take 100μl and add it to the next row. Repeat the above steps until the volume of the last column becomes 300μl; let the 96-well plate stand for 15 minutes and observe and count under a microscope. Take the volume corresponding to 100 cells and add it to 20ml of the 1640 medium (containing 10% fetal bovine serum and 1% Glutamax) described above, mix well and plate, 200μl per well. After one week, observe under a microscope, determine and mark the monoclonal wells, and pick out the positive wells to be tested.
[0318] In vitro screening
[0319] Hybridoma cells expressing specific anti-CD40L antibodies were screened using ELISA and flow cytometry.
[0320] Hybridoma sequencing
[0321] RNA extraction: Take about 5×10 freshly cultured cells 6The pellet was centrifuged at 300g for 5 minutes. The supernatant was removed and 500μl of LY buffer (Biomiga) (20μl of β-mercaptoethanol per 1ml before use) was added to the pellet and mixed until clear. The pellet was added to a DNA removal tube and centrifuged at 13,000rpm for 2 minutes. The flow-through was collected. 100% ethanol was added to the flow-through at a ratio of 1 / 2 and mixed by inverting five times until clear. The clarified solution was added to an RNA collection tube and centrifuged at 13,000rpm for 1 minute to remove the liquid. 500μl of RB (Recovery Buffer) (Takara) was added and centrifuged at 13,000rpm for 30 seconds. 500μl of RNA Wash Buffer (Biomiga) (with appropriate amount of ethanol added before use) was added and centrifuged for 30 seconds. This process was repeated once. After thorough centrifugation to remove the ethanol, 30μl of DEPC water was added to a collection column (from the PrimeScript II 1st Strand cDNA Synthesis Kit) and centrifuged at 12,000g for 2 minutes to collect the eluate. Determine RNA concentration.
[0322] cDNA was obtained by reverse transcription using the PrimeScript II 1st Strand cDNA Synthesis Kit (Takara). After incubation at 65°C for 5 minutes, the cDNA was immediately cooled on ice. Reaction System I was added to the reverse transcription system in a total volume of 20 μl. After gentle mixing, reverse transcription and translation were performed under the following conditions: 42°C for 60 minutes and 95°C for 5 minutes. The cDNA was then cooled on ice to obtain cDNA. The cDNA was ligated into a T-vector, and the heavy and light chain variable regions were amplified by PCR using the Mighty TA-cloning Kit (Takara).
[0323] Transformed cells
[0324] Remove the TOP10 competent cell (Tiangen Biotech (Beijing) Co., Ltd.) from -80°C and thaw on ice. Add 5 μl of the ligation product obtained above to the thawed TOP10 competent cell, mix thoroughly, and incubate on ice for 30 minutes. Heat shock at 42°C for 90 seconds, then quickly cool on ice for 2 minutes. Add 900 μl of LB medium (Sangon Biotech (Shanghai) Co., Ltd.) to the EP tube and incubate at 37°C at 220 rpm for 1 hour. Centrifuge at 3000 g for 2 minutes, remove 800 μl of the supernatant, resuspend the cells in the remaining medium, and plate on an ampicillin-resistant plate. Incubate overnight at 37°C, and select clones for sequencing.
[0325] Construction of chimeric antibodies
[0326] Using molecular biology techniques, the sequence of the anti-CD40L antibody produced by the hybridoma cells was obtained. The VH and VL region sequences of the sequenced candidate anti-CD40L antibody were combined with the hIgG1 sequence (mutation sites: L234A / L235A / ΔP329, SEQ ID NO: 5) to construct a human-mouse chimeric antibody.
[0327] Chimeric antibody screening
[0328] ELISA and Luciferase in vitro assays were used for screening to obtain anti-CD40L antibodies that could both bind to CD40L and block CD40-CD40L interaction.
[0329] Humanization of chimeric antibodies
[0330] The obtained chimeric antibody is humanized. Humanization is performed by the following steps:
[0331] ① Determine the CDR loop structure;
[0332] ② Find the closest homologous sequence for each V / J region of the heavy and light chains in the human germline sequence database;
[0333] ③ Screening for the human germline that best matches the heavy and light chains and the lowest amount of back mutations;
[0334] ④ Constructing the CDR region of the chimeric antibody onto the human framework region;
[0335] ⑤ Using sequence and structural features, determine the amino acid positions in the framework region that maintain CDR function;
[0336] ⑥ Perform back mutation at the sequence position determined to be important (return to the input amino acid type);
[0337] ⑦Optimize amino acids at risk sites.
[0338] Finally, humanized antibodies Hz33B9C5 and Hz47E2 that bind to human CD40L were obtained. The CDRs, light chain variable regions, heavy chain variable regions, amino acid sequences of the light and heavy chains, and corresponding nucleotide sequences of the two humanized antibodies (Hz33B9C5 and Hz47E2) exemplified in the present invention are all listed in the sequence listing.
[0339] Example 2: ForteBio determination of the binding kinetics of the antibody of the present invention and the antigen
[0340] The equilibrium dissociation constant (KD) of the antibody of the present invention binding to human CD40L was determined using thin-layer biofilm interferometry (ForteBio).
[0341] According to the number of samples, the corresponding AMQ (Pall, 1506091) or AHQ (Pall, 1502051) (for positive control detection) sensors were prepared and immersed in SD buffer (PBS 1×, BSA 0.1%, Tween-20 0.05%).
[0342] 100 μl of SD buffer, antibodies (Hz33B9C5 and Hz47E2, 100 nM), and antigen (human CD40L, purchased from Acrobiosystems, 100 nM) were added to a 96-well black polystyrene half-well microplate (Greiner, 675076) at a loading volume of 200 μl. The plate was arranged according to the sample positions and the sensor positions were selected. The instrument parameters were set as follows: Run steps: Baseline, Loading ~1 nm, Baseline, Association, and Dissociation; the run time for each step depended on the sample association and dissociation rates. The rotation speed was 400 rpm and the temperature was 30°C. KD values were analyzed using ForteBio analysis software.
[0343] In the experiments described in the above assays, the affinities of Hz33B9C5 and Hz47E2 are shown in Table X:
[0344] Table 1. Affinity constants (equilibrium dissociation constants) of antigen-antibody binding assays by ForteBio
[0345] Example 3: The antibodies of the present invention inhibit the binding of CD40 and CD40L at the molecular level
[0346] In the present application, the inventors of the present invention screened antibodies with higher affinity for CD40L through mouse hybridoma technology, and finally obtained two humanized antibodies Hz33B9C5 and Hz47E2 through humanization transformation. The specific sequences are shown in the sequence listing.
[0347] Expression and purification in ExpiCHO cells were as follows:
[0348] The sequences of Hz33B9C5 and Hz47E2 were cloned into pcDNA3.1 vector for later use. Take ExpiCHO cells and check that the cell density reaches 8.0-10x10 6 viable cells / mL, the viability should be between 95-99%, and the cell density should be adjusted to 6.0x10 6viable cells / mL. In a container of appropriate size, add transfection buffer (Fectamine, source: Gibco) at 8% of the transfected cell volume. Add the corresponding amount of plasmid to the transfected cells at 0.8 μg / mL. Filter the transfection buffer containing the DNA plasmid through a 0.22 μm filter into a new, clean container to sterilize. Add transfection reagent (FectPro, source: Polyplus) at 3.2 μL / mL to the filtered mixture and let it stand for 10 minutes. Rapidly add the complex of transfection reagent and plasmid DNA to the cells, gently shaking the shaker. Incubate at 36.5°C in a shaker with 8% CO2. After 18-22 hours of incubation, add Enhancer (source: Gibco) at 6 μL / mL cell volume and Feed (source: Gibco) at 300 μL / mL cell volume. On day 7, collect the cell supernatant. Purify the protein by affinity chromatography to obtain the final antibody molecule. The purified antibody solution was centrifuged at 4000 rpm / min for 10 minutes using a 15 ml ultrafiltration centrifuge tube. The protein was diluted with PBS and centrifuged again at 4000 rpm / min for 10 minutes. This operation was repeated several times to replace the buffer. The antibodies after buffer replacement were combined and the antibody concentration was measured. The components of the monoclonal antibody were further characterized by liquid chromatography-mass spectrometry (LC-MS) and size exclusion chromatography (SEC), and quantified by ultraviolet-visible spectrophotometer (UV spectrophotometer).
[0349] In this example, its molecular blocking effect on CD40L was tested. INX-021 was used as a control (see the sequences in Figures 1A and 1B of WO2017011544A1). Antigen (human CD40 Ligand) Source: Commercial antigen: Acro Human CD40 Ligand / TNFSF5 Protein, His, Flag Tag (active trimer) (MALS verified).
[0350] Equipment: Thermo Fisher MULTISKAN-FC
[0351] Reagents and raw materials:
[0352] The details of the method are as follows:
[0353] a) Antigen coating: Dilute Human CD40 Ligand to 1 μg / ml in 1X PBS, add 100 μl / well to a 96-well ELISA plate, seal the plate and incubate at 4°C overnight.
[0354] b) Blocking: Discard the supernatant from the plate, wash three times with PBST, add 1% BSA (300 μl / well), and block for 2 h.
[0355] c) Prepare the primary antibody: Starting at 20 μg / ml, dilute the test antibody in a 2-fold series with 1% BSA. Dilute Biotinylated Human CD40 to 2 μg / ml with 1% BSA.
[0356] d) Primary Antibody Incubation: Discard the supernatant and wash the plate six times with PBST. Then, add 50 μl of antibody per well, followed by 50 μl of Biotinylated Human CD40 per well, and incubate for 2 h.
[0357] e) Prepare enzyme-labeled antibody: Dilute HRP Streptavidin 1:3000 in 1% BSA.
[0358] f) Enzyme-labeled antibody incubation: Discard the supernatant, wash the plate three times with PBST, add 100 μl / well of diluted HRP Streptavidin, and incubate for 1 hour;
[0359] g) Color development: Discard the supernatant from the plate, wash three times with PBST, add 100 μl / well of TMB colorimetric solution, and develop for 5-10 min. After complete color development, add 50 μl / well of stop solution, and read the plate in a microplate reader at 450 nm.
[0360] As shown in Figure 1, the antibodies Hz33B9C5 and Hz47E2 of the present invention exhibited lower CD40 protein binding percentages compared to the positive control INX-021, indicating that Hz33B9C5 and Hz47E2 better inhibited the binding of CD40 protein to its ligand, CD40L protein. In summary, compared to the positive control INX-021, the antibodies Hz33B9C5 and Hz47E2 of the present invention exhibited superior target blocking activity.
[0361] Example 4: Antibodies of the present invention inhibit downstream signaling activation in Jurkat cells overexpressing CD40 at the cellular level
[0362] The Jurkat-NFκB-Luc reporter system was used to assess the inhibitory activity of Hz33B9C5 and Hz47E2, anti-CD40L antibodies, on activation of CD40 downstream signaling pathways. In the absence of anti-CD40L antibodies, CD40-overexpressing Jurkat-NFκB-Luc cells stimulated by CHO-CD40L cells produce luciferase, which catalyzes substrate luminescence. When the anti-CD40L antibodies bind to CD40L overexpressed on the surface of CHO cells, they inhibit the interaction of CD40L with the membrane protein of CD40-overexpressing Jurkat-NFκB-Luc cells, resulting in decreased luciferase secretion. Therefore, the luciferase reporter system can be used to assess the inhibition of cell activation by Hz33B9C5 and Hz47E2.
[0363] Construction of CD40L-overexpressing CHO-CD40L cell line:
[0364] The CD40L protein sequence (SEQ ID NO:27) was cloned into the PXC17.4 vector. The prepared vector plasmid was co-incubated with Pvul-HF in diluted CutSmart Buffer for enzymatic digestion. GS-CHO cells (source: Lonza) were centrifuged, the supernatant removed, and the cells gently resuspended in CD CHO Medium containing 1% SP4. The enzymatically digested plasmid was added to the cells, mixed thoroughly, and transferred to an electroporation cuvette. Electroporation was performed using an electroporator set to 300V, 900uF, and resistance infinity. Immediately after electroporation, the cells were transferred to prewarmed CD CHO Medium containing 1% SP4 and incubated on a shaker at 120 rpm at 37°C in 6% CO2. After 1-2 days of culture, the medium containing MSX was replaced for selection. Cell viability will initially decrease and then recover. Once viability has recovered to above 95%, the cells were frozen for future use.
[0365] Construction of the CD40-overexpressing Jurkat-Luc-CD40 cell line:
[0366] The CD40 protein sequence (SEQ ID NO: 32) was cloned into the pLVX-IRES-EGFP vector. The prepared vector plasmid was mixed with pSPAX, pMD2.G, PEIpro, and Opti-MEM and transfected into 293T cells for viral packaging. After 48 hours, the virus was collected and concentrated, and then infected with the NFkB Reporter Jurkat cell line (Source: Yoshiman Bio). Cells with fluorescent signals were selected by flow cytometry, expanded in culture, and frozen for future use.
[0367] In a co-culture system constructed by overexpressing CHO-CD40L and Jurkat-Luc-CD40 cells, the addition of the antibody of the present invention blocked the binding of CD40L on the surface of CHO cells and CD40 on the surface of Jurkat-NFκB-Luc, thereby inhibiting downstream NFκB activation and luciferase production in Jurkat cells, and reducing the fluorescence signal of the system. Figure 2 shows the experimental results.
[0368] The details of the method are as follows:
[0369] a) Culture the cells until the logarithmic growth phase and adjust the cell number using 1640 complete medium: Jurkat-Luc-CD40 is adjusted to 1*10^5 cells / 45ul, and CHO-CD40L is adjusted to 5000 cells / 45ul.
[0370] b) Antibody preparation: Prepare the antibody at a concentration of 200 μg / ml using 1640 complete medium and dilute it 2-fold for later use.
[0371] c) Sample Addition: First, remove the CHO-CD40L cells and gently pipette 5-7 times. Add 45 μl per well to a 96-well plate. Next, add 10 μl / well of the prepared antibody diluent and pipette 5 times to mix thoroughly. Finally, remove the Jurkat-Luc-CD40 cells and gently pipette 5-7 times. Add 45 μl to each well of the 96-well plate and pipette 5 times to mix thoroughly. Place the 96-well plate in a 37°C, 5% CO2 cell incubator for 6 hours.
[0372] d) After 6 hours of reaction, remove the 96-well plate and equilibrate to room temperature. Add Bio-Glo in a 1:1 volume ratio. TM Luciferase Assay System, react at room temperature for 10 minutes and read the result.
[0373] Equipment: Fluorescence quantitative microplate reader SPARK
[0374] Reagents and raw materials:
[0375] The results are shown in Figure 2. Compared with the positive control INX-021, the antibody molecules Hz33B9C5 and Hz47E2 of the present invention more strongly inhibited the downstream NFkB signaling activation of cells overexpressing CD40, indicating that the antibody molecules of the present invention can significantly inhibit the CD40 downstream signaling activation mediated by CD40L.
[0376] Example 5: Inhibition of the expression of B cell activation marker CD86 by the antibodies of the present invention
[0377] Flow cytometry (FACS) was used to examine the inhibitory effects of anti-CD40L antibodies Hz33B9C5 and Hz47E2 on B cell activation in an in vitro culture system of peripheral blood mononuclear lymphocytes (PBMCs). When B cells receive stimulation signals, expression of the activation marker CD86 on their surface increases rapidly. However, in the presence of anti-CD40L antibodies, B cell activation is suppressed. Therefore, measuring the proportion of CD86 expression on the B cell surface can reflect the inhibitory effect of the antibodies. Figure 3 shows the experimental results.
[0378] The details of the method are as follows:
[0379] a) PBMCs were rapidly thawed in a 37°C water bath, added to 9 ml of complete culture medium, centrifuged at 300 g for 5 min, discarded the supernatant, and resuspended in complete culture medium (RPMI supplemented with 10% fetal bovine serum). The cells were plated at a density of 5 x 10 cells per well in a 96-well plate (U-shaped).
[0380] b) CHO-CD40L cells were added to the above-mentioned well plate at a density of 5 x 10^3 cells per well and pipetted evenly with a pipette;
[0381] c) Dilute the test antibody at different concentrations and add it to the above well plate, pipette evenly, and incubate for 18 hours;
[0382] d) Staining, flow cytometry (PC5.5 CD19, PE CD86, LIVE / DEAD TM Fixable Near-IR Dead Cell Stain Kit) for on-machine detection.
[0383] Equipment: Beckman Cytoflex
[0384] Reagents and raw materials:
[0385] As shown in FIG3 , the antibody molecules Hz33B9C5 and Hz47E2 of the present invention can dose-dependently inhibit the expression of CD86 in B cells, indicating that they significantly inhibit the early activation of B cells, and the inhibitory effect is similar to that of the positive control INX-021.
[0386] Example 6: Effect of the Antibody of the Present Invention on the Proliferation of B Cells Isolated in Vitro
[0387] B cells proliferate rapidly during class switching and differentiation into plasma cells. By isolating B cells from peripheral blood mononuclear lymphocytes and culturing them in vitro under certain conditions, in the presence of primary and secondary signals, as well as cytokines, B cells rapidly proliferate. The addition of Hz33B9C5 or Hz47E2 blocks the interaction of CD40L, the secondary signal, with CD40 on the B cell surface, thereby inhibiting B cell proliferation. Figure 4 shows the experimental results.
[0388] The details of the method are as follows:
[0389] a) Thaw PBMCs in a 37°C water bath, add to 9 ml of complete culture medium, centrifuge at 300 g for 5 min, discard the supernatant, and resuspend in MACs buffer.
[0390] b) Isolate B cells from PBMCs using the B cell isolation kit II protocol, count them, and incubate them with 10 mL of complete culture medium containing 0.5 μg / mL Anti-IgM (AffiniPure F(ab')2Fragment Goat Anti-Human IgM) at 4°C for 2 h.
[0391] c) The treated cells were washed and counted, and B cells were diluted at 5e+5 / ml in a culture medium containing 1 μg / mL Anti-IgM, 160 ng / mL Recombinant Human IL-21 Protein, and 2 μg / mL CD40L.
[0392] d) Each antibody was diluted 2-fold with PBS at 20 μg / ml in the first well, and then 100 μL of antibody and 100 μL of B cells were added to a 96-well white-bottom plate.
[0393] e) On the fourth day of culturing, fresh culture medium with the same antibody concentration as the culture medium in step d) above was prepared, and half of the culture medium was replaced.
[0394] f) On the seventh day, centrifuge the plate and carefully discard 60ul of supernatant from each well, then add 100ul Luminescent Cell Viability Assay: pipette up and down 3-5 times, let it rest at room temperature for 10 minutes, and then read the results on a microplate reader.
[0395] Equipment: Fluorescence quantitative microplate reader SPARK
[0396] Reagents and raw materials:
[0397] The results are shown in Figure 4. The kit detected the cell number and found that Hz33B9C5 and Hz47E2 could dose-dependently inhibit B cell proliferation induced by CD40L signaling in an in vitro B cell culture system, and the inhibitory effect was comparable to that of the positive control INX-021.
[0398] Example 7: Effect of the antibodies of the present invention on the differentiation of B cells into plasma cells
[0399] Under appropriate conditions, B cells differentiate into plasma cells, which ultimately produce antibodies. Antibodies secreted by plasma cells are the primary mode of action in humoral adaptive immunity. B cells isolated from PBMCs were stimulated with 3T3-CD40L cells, anti-IgM (AffiniPure F(ab')2Fragment Goat Anti-Human IgM, Fc5μfragment specific), and IL-21 to differentiate into plasma cells. Simultaneous addition of anti-CD40L antibodies, Hz33B9C5 or Hz47E2, inhibited the interaction between 3T3-CD40L and B cells, thereby reducing B cell differentiation into plasma cells. Figure 5 shows the experimental results.
[0400] Construction of 3T3-CD40L cell line overexpressing CD40L:
[0401] a) Lentivirus packaging
[0402] 1) Plate one T175 flask of 293T cells;
[0403] 2) When the cell density reaches greater than 80%, perform transfection. Before transfection, discard the culture medium in the T175 flask, add 20 ml of basal DMEM medium (serum-free and antibiotic-free), and return to the incubator at 37°C and 5% CO2.
[0404] 3) preparing a transfection mixture in which the ratio of plasmid:pSPAX2:pMD2.G:PEIpro is 2:2:1:15 and the total volume of the transfection mixture is 10% of the total culture volume;
[0405] 4) Gently drop the prepared transfection mixture into the culture flask; gently shake the culture flask to evenly distribute it, and place it in a 37°C, 5% CO2 incubator for incubation;
[0406] 5) 6 h after transfection, the culture medium in the culture flask was aspirated and 20 ml of fresh DMEM medium containing 4% FBS was added. The cells were then incubated at 37°C in a 5% CO2 incubator.
[0407] b) Collect viruses and infect 3T3 cells (Source: Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences)
[0408] 1) Prepare 3T3 cells 1 day before infection and plate the cells into 6-well plates; 4 wells are for the experimental group and 2 wells are for the negative control group;
[0409] 2) On the day of infection, the viral supernatant obtained from the cells in step a) was collected and centrifuged (500 g, 10 min) to remove dead cells;
[0410] 3) Add the viral supernatant after centrifugation to the 3T3 cells. Add 2 ml of viral supernatant to the experimental group wells; add 2 ml of culture medium to the negative control group wells. Transfer the cells to the incubator.
[0411] 4) One day after viral infection, the medium was changed to complete culture medium (10% FBS containing antibiotics);
[0412] c) Cell sorting
[0413] 1) After the cells have stably expanded, they are collected by centrifugation and stained for CD40L on the cell surface using a flow cytometry antibody;
[0414] 2) Use a flow cytometry instrument to sort and select cells with fluorescent signals;
[0415] 3) Expanding the culture of the sorted cells; obtaining 3T3-CD40L cells, and freezing them for future use.
[0416] The details of the method are as follows:
[0417] a) 3T3-CD40L cells were treated with 10 μg / ml mitomycin C at 37°C for 30 min and seeded in a 96-well plate at 6250 cells / well.
[0418] b) The next day, prepare B cell basal medium: 50 ml RPMI1640 + 0.192 μl 2-mercaptoethanol + 100 μl HEPES. All the following reagents are prepared using this medium.
[0419] c) B cells were isolated from PBMCs using a B cell isolation kit II. The cells were treated with 10 mL of B cell basal medium containing 0.5 μg / mL anti-IgM at 4°C for 2 h. The cells were washed, counted, and diluted at 1e+6 / mL in B cell basal medium containing 160 ng / mL IL-21.
[0420] d) Prepare each antibody at 40 μg / ml in the first well, then dilute it in a 2-fold gradient, 12 times. Aspirate the medium from the 96-well plate containing 3T3-CD40L cells, and add 100 μL of antibody plus 100 μL of B cells to each well. Add slowly and do not pipette.
[0421] e) After culture on D4, replace half of the B cell basal medium.
[0422] f) The cells on day 7 of differentiation were subjected to IgD (BB515 Mouse Anti-Human IgD, 1:100), CD38 (Brilliant Violet 785 TM The cells were stained with anti-human CD38 Antibody, 1.5:100), CD19 (CD19-PE-CF594, 1:100), and DCM (DCM APC-Cy7, 1:1000) and analyzed by flow cytometry.
[0423] Equipment: BD Symphony
[0424] Reagents and raw materials:
[0425] As shown in Figure 5, similar to the positive controls INX-021 and MEDI4920 (shown in SEQ ID NO: 145 in CN103874501B), the antibody molecules Hz33B9C5 and Hz47E2 of the present invention inhibited the differentiation rate of plasma cells in a concentration-dependent manner. This indicates that by inhibiting the interaction between 3T3-CD40L and B cells, the antibodies of the present invention can reduce the differentiation of B cells into plasma cells.
[0426] Example 8: Effect of the Antibody of the Present Invention on IL-12 Secretion by MoDC Cells
[0427] Although CD40 is mainly expressed on B cells, CD40 and CD40L expressed by DC cells, which also serve as antigen-presenting cells, also play a role in immune system responses in many cases. IL-12 secreted by DC cells acts on receptors on T cells and NK cells, causing T cell differentiation and NK cell IFN-γ and TNF-α secretion, promoting inflammatory responses. In this experiment, monocytes were isolated from peripheral blood mononuclear cells, differentiated into moDC cells under the induction of IL-4 and GM-CSF, and co-cultured in the presence of CD40L protein and the antibody of the present invention. The concentration of IL-12 secreted by DC cells was detected by ELISA. Figure 6 shows the experimental results.
[0428] The details of the method are as follows:
[0429] a) Thaw PBMCs (50M / tube) and negatively isolate monocytes using a Pan monocyte isolation kit;
[0430] b) Resuspend the cells in X-VIVO medium and plate them in a 6-well plate. Add 100 ng / ml GM-CSF and 10 ng / ml IL-4 to the cells for induction for 7 days, supplementing them with 1 ml of medium supplemented with 100 ng / ml GM-CSF and 10 ng / ml IL-4 on Day 2 and Day 4.
[0431] c) Collect the induced imDC cells obtained in b), resuspend the cells in X-VIVO medium, and adjust the cell density to 2.5*10^5 / ml.
[0432] d) Add the DC cell suspension obtained in c) to a 96-well flat-bottom plate at 100 μl / well.
[0433] e) 4ug / ml CD40L was prepared using RPMI1640 medium containing 10% FBS, 50 μl / well, and the final concentration of the system was 1ug / ml.
[0434] f) Dilute the test antibody to 20 μg / ml using X-VIVO medium. Add 50 μl of the diluted antibody to the cells, mix well, and incubate at 37°C.
[0435] g) After culturing for 4 days, the cell culture supernatant was collected and the IL-12p40 content was detected using a commercial ELISA kit (Human IL-12 / IL-23p40 ELISA kit).
[0436] Equipment: Thermo Fisher MULTISKAN-FC
[0437] Reagents and raw materials:
[0438] As shown in Figure 6, compared with the positive control INX-021, the antibody molecules Hz33B9C5 and Hz47E2 of the present invention more strongly inhibited the secretion of IL-12 by DC cells, indicating that the antibodies of the present invention can more significantly inhibit IL-12, thereby inhibiting a series of inflammatory reactions mediated by IL-12.
[0439] Example 9: The antibodies of the present invention do not cause platelet activation in in vitro experiments
[0440] The antibodies of the present invention were tested for platelet activation using two assays: platelet activation marker expression and aggregation assay using a whole-blood platelet aggregation assay. Platelets were treated with positive and negative control drugs, and the expression of platelet activation markers CD62P and PAC1 was then quantitatively analyzed using flow cytometry. A whole-blood platelet aggregation assay was also used for real-time monitoring and quantitative analysis. Figures 7-9 show the experimental results.
[0441] The details of the method are as follows:
[0442] a) Human platelets were resuspended in Tyrode's buffer (Sodium Chloride (140 mM), Potassium Chloride (5 mM), HEPES (25 mM), Calcium Chloride Dihydrate (2 mM), Magnesium Chloride Hexahydrate (2 mM), Dextrose / Glucose (10 mM), Water (rest)) and stored at room temperature. The platelet suspension was centrifuged at 3000 rpm for 2 min. The precipitated platelets were gently resuspended in PBS and counted using a three-differential hematology analyzer, typically 3 x 10 11 / L.
[0443] b) CD40L antigen and the test antibody were mixed evenly at a molar ratio of 1:1, so that the final concentration of CD40L and the final concentration of the antibody drug were both 3 μM, and the mixture was allowed to stand at room temperature for 15 minutes to activate the antibody drug to form an immune complex.
[0444] c) Platelet aggregation analysis system analysis: Preheat the aggregometer Chrono-Log 560Ca to 37°C. Gently mix 200 μL of platelets and 50 μL of antigen-antibody complex in a colorimetric tube at a stirring speed of 1000 rpm. Add CaCl2 to a final concentration of 1 mM. Use a colorimetric tube containing PBS as a control to reset the baseline, and record the change in colorimetric tube transmittance over time.
[0445] d) Flow cytometry analysis: Prepare 10 μL of antigen-antibody complex using the above ratios and add CaCl2 to a final concentration of 1 mM. Mix 50 μL of platelets with this 10 μL system and incubate at 37°C in a water bath for 10 min. Add 2.5 μL of P-selectin and PAC-1 flow cytometry antibodies and incubate at room temperature in the dark for 15 min. Dilute and mix thoroughly with 300 μL of PBS and place on a flow cytometer.
[0446] Equipment: Sysmex three-category hematology analyzer (model: KX-21N), Chrono-Log whole blood platelet aggregation analysis system (model: Chrono-Log 560Ca), BD flow cytometer (model: FACS Calibur)
[0447] Reagents and raw materials:
[0448] As shown in the FACs results in Figures 7-8 , the antibodies Hz33B9C5 and Hz47E2 of the present invention showed little effect on the expression of platelet activation markers PAC-1 and CD62P compared to the positive controls, Convulxin and Rupilzumab. Furthermore, the antibodies of the present invention exhibited similar performance to INX-021, an Fc-mutated antibody. Furthermore, Figure 9 demonstrates that the antibodies of the present invention exhibited substantially the same platelet aggregation ratio as the negative control, PBS. This ratio is comparable to that of INX-021 and significantly lower than that of Convulxin and Rupilzumab. This indicates that the immune complexes formed by the antibodies of the present invention with CD40L do not cause platelet aggregation or activation.
[0449] Example 10: Data of the antibodies of the present invention in the experimental autoimmune encephalomyelitis (EAE) mouse model
[0450] Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that causes encephalitis and demyelination. MS is considered an autoimmune disease caused by autoreactive T cells. Symptoms include muscle stiffness and paralysis, visual impairment and blindness, sensory loss, and ataxia, characterized by recurrent relapses. Several distinct animal models of MS exist. Among them, the experimental autoimmune encephalomyelitis (EAE) model is widely used in MS research because it shares similar pathological features of inflammation and demyelination with MS. EAE is induced by immunization with myelin proteins (in this study, myelin oligodendrocyte glycoprotein MOG) or peptides of these proteins. This is likely due to the activation of myelin-specific T cells in the periphery, which cross the blood-brain barrier and enter the central nervous system, where they are reactivated, triggering a series of inflammatory responses that lead to demyelination and axonal apoptosis, ultimately leading to neurological damage and loss of function. Clinical symptoms are assessed using standardized scoring systems to measure the degree of disease induction.
[0451] The scoring criteria for the experimental autoimmune encephalomyelitis (EAE) model mice used in this experiment are as follows:
[0452] 0 points: Mouse health
[0453] 1 point: The mouse's tail is weak
[0454] 2 points: One hind limb of the mouse is paralyzed
[0455] 3 points: Both hind limbs of the mouse are paralyzed
[0456] 4 points: The mouse loses 20% or more of its body weight
[0457] 5 points: Mouse is dead or dying
[0458] In addition, the health status of the mice can be indirectly indicated by measuring their weight, and the inhibitory effect of the antibodies of the present invention on the antibody production function of the mice can be reflected by detecting the titer of anti-MOG antibodies in the peripheral blood serum of the mice. Figures 10-12 show the experimental results.
[0459] The details of the method are as follows:
[0460] a) Reagent configuration:
[0461] 1. Inactivated tuberculosis stock solution (H37Ra stock solution) (100 mg / ml): 10 ml complete Freund's adjuvant + 100 mg H37Ra dissolved by ultrasonication;
[0462] 2. MOG35-55 stock solution (10 mg / ml): 5 ml complete Freund's adjuvant + 50 mg MOG35-55;
[0463] 3. Pertussis virus stock solution (PTX stock solution) (100 μg / ml): 50 μg PTX + 500 μl DPBS (stored in aliquots at -40°C).
[0464] 4. Inactivated Mycobacterium tuberculosis working solution (H37Ra): 500ul complete Freund's adjuvant + 500ul inactivated Mycobacterium tuberculosis stock solution;
[0465] 5. MOG35-55 emulsifier: 2ml MOG35-55 emulsifier = 200ul MOG35-55 mother solution + 800ul DPBS + 1ml H37Ra working solution, use after fully emulsifying;
[0466] 6. Pertussis virus working solution (PTX working solution): 30ul PTX mother solution + 1970ul DPBS (prepared and used immediately)
[0467] b) Model method:
[0468] 1. Five female mice aged 8-10 weeks were administered with control (PBS), hIgG, INX-021, Hz33B9C5, and Hz47E2 at a dose of 10 mg / kg per group.
[0469] 2. Day 0: Inject 100 μl of MOG35-55 emulsifier into two points on the back, inject 200 μl of PTX working solution into the tail vein, and administer antibodies or control IP.
[0470] 3. Day 3: Inject PTX working solution into tail vein and administer antibody or control IP;
[0471] 3. Day 7 and Day 10, IP administration of antibodies or controls;
[0472] 4. On Days 0, 3, 7, 10, and 12-21, the severity of the disease was evaluated using a 0-5 score system and the weight of the mice was recorded;
[0473] 5. On Day 7, Day 14, and Day 21, blood was collected from the mouse orbits to collect serum, and the titer of Anti-MOG antibody in the serum was detected by ELISA.
[0474] Equipment: Thermo Fisher MULTISKAN-FC
[0475] Reagents and raw materials:
[0476] As shown in Figures 10-11, administration of the antibodies Hz33B9C5 and Hz47E2 of the present invention at 10 mg / kg can significantly reduce the clinical score of experimental autoimmune encephalomyelitis (EAE) without affecting the body weight of mice. These effects are close to those of the control group without MOG induction and are better than the positive control INX-021. These results indicate that Hz33B9C5 and Hz47E2 have the ability to improve experimental autoimmune encephalomyelitis (EAE) and autoimmune diseases such as multiple sclerosis (MS).
[0477] As shown in Figure 12, by administering the antibodies Hz33B9C5 and Hz47E2 of the present invention at a dose of 10 mg / kg, the antibodies of the present invention had lower anti-MOG antibody titers than INX-021 14 days after immunization, especially 21 days after immunization. This indicates that the antibodies of the present invention have a stronger inhibitory effect on humoral immunity than INX-021, and preferably have a stronger effect of inhibiting antibody production.
[0478] Example 11: The antibodies of the present invention inhibit the production of anti-hemocyanin antibodies in mice
[0479] Because peptides, small proteins, and some drug molecules are haptens and generally non-immunogenic, they require the aid of a carrier protein, such as hemocyanin, to stimulate an immune response in the form of antibodies. Therefore, hemocyanin (KLH) is widely used in research, biotechnology, and therapeutic applications. Furthermore, because hemocyanin originates from limpets (a type of gastropod), whose growth and development differ significantly from mammals, it is less likely to produce false-positive results in certain mammalian immunological studies.
[0480] After injection of the antibody of the present invention into humanized CD40 / CD40L mice and subsequent immunization with hemocyanin, the antibody of the present invention inhibits the interaction between CD40L and CD40, thereby inhibiting B cell maturation and differentiation and the secretion of anti-hemocyanin antibodies. FIG13 shows the experimental results.
[0481] The details of the method are as follows:
[0482] a) Reagent preparation: Dissolve 250 μg of hemocyanin per mouse in 100 μl of PBS.
[0483] b) Model method:
[0484] 1. Each group consisted of 5 mice, aged approximately 8-10 weeks, who were administered control hIgG, INX-021 (3 mpk), or Hz33B9C5 (0.3 mpk, 1 mpk, and 3 mpk) respectively.
[0485] 2. Day 0: Mix the hemocyanin stock solution and alum adjuvant at a volume ratio of 1:1 and inject intraperitoneally. At the same time, administer the antibody drug to the mice IP.
[0486] 2. Day 7: IP injection of antibody drugs into mice;
[0487] 3. On Day 7, Day 14, and Day 21, blood was collected from the mouse orbits to collect serum, and the titer of Anti-MOG antibody in the serum was detected by ELISA.
[0488] Equipment: Thermo Fisher MULTISKAN-FC
[0489] Reagents and raw materials:
[0490] As shown in Figure 13, in humanized CD40 / CD40L mice, the Hz33B9C5 antibody of the present invention resulted in lower concentrations of anti-KLH IgG in mouse serum compared to INX-021. This suggests that the antibody of the present invention can more effectively inhibit the interaction between CD40L and CD40, thereby inhibiting B cell maturation and differentiation via the T cell-dependent pathway, ultimately reducing the production of anti-hemocyanin antibodies. Furthermore, the titers of anti-KLH IgG in mouse serum showed a dose-responsive trend across different Hz33B9C5 dose groups, demonstrating that the efficacy of Hz33B9C5 in this animal model is dose-dependent.
[0491] Example 10: Pharmacokinetics of the Antibody of the Invention in Mice
[0492] Experimental Materials
[0493] Reagent and consumables information
[0494] Instrument and equipment information
[0495] Experimental Preparation
[0496] 2.1 1× PBS buffer
[0497] Add 100 mL of 10× PBS buffer, dilute to 1 L, and mix thoroughly.
[0498] 2.2 Coating fluid
[0499] Take one packet of carbonate powder, dissolve it in 400 mL of ultrapure water, dilute to 500 mL, and mix well.
[0500] 2.3 Lotion
[0501] Take 1 mL of Tween-20 and add it to 1999 mL of 1× PBS buffer and mix well.
[0502] 2.4 Blocking solution
[0503] Weigh 5 g of skim milk powder, dissolve it in 100 mL of washing solution, and mix well.
[0504] 2.5 Sample diluent (antibody diluent)
[0505] Weigh 1 g of BSA, dissolve it in 100 mL of washing solution, and mix well.
[0506] Experimental process
[0507] 3.1.1 Pre-coating: Coat a 96-well ELISA plate one day in advance. Dilute the CD40L protein to 1 μg / mL using coating solution. Add 100 μL per well, seal the plate with sealing film, and incubate at 4°C overnight.
[0508] 3.1.2 Washing: Pour out the pre-coating solution in the 96-well ELISA plate, pat dry on absorbent paper, then add 300 μL of washing solution to each well, shake and mix for 10 seconds, pat dry, and repeat washing three times.
[0509] 3.1.3 Blocking: Add blocking solution with a pipette, 200 μL per well, seal the plate with sealing film, and incubate at 4°C overnight or at room temperature for 2 hours.
[0510] 3.1.4 Wash the plate: Repeat 3.1.2.
[0511] 3.1.5 Sample addition: Add 100 μL of diluted standards (Hz33B9C5 and Hz47E2, concentrations of 1-512 ng / ml, 10 concentrations, 2-fold dilutions), quality control samples (Hz33B9C5 and Hz47E2, 5.12-200 ng / ml, 5 concentrations, 2-fold dilutions), and test samples (serum obtained by orbital bleeding of mice at a certain time) to each well and incubate at room temperature for 2 hours, protecting from light.
[0512] 3.1.6 Washing: Pour out the solution in the 96-well ELISA plate, pat dry on absorbent paper, then add 300 μL of washing solution to each well, shake and mix for 10 seconds, pat dry, and repeat washing 6 times.
[0513] 3.1.7 Add enzyme-labeled antibody for incubation: Add 100 μL of diluted Goat anti-Human IgG Fc-HRP (25 ng / mL) to each well and incubate at room temperature for 1 hour, protecting from light.
[0514] 3.1.8 Wash the plate: Repeat 3.1.6.
[0515] 3.1.9 Color development: Add TMB substrate to a 96-well ELISA plate, 100 μL per well, and develop color at room temperature in the dark for 5-10 minutes.
[0516] 3.1.10 Termination: Add 50 μL of ELISA stop solution to each well, shake at medium speed for 10 seconds, and read the OD450 nm / 620 nm value within 30 minutes.
[0517] Result Analysis
[0518] 4.1 The measured concentration value shall be rounded to 4 decimal places, and the average concentration value shall be rounded to 2 decimal places, and expressed as “Mean”.
[0519] 4.2 Optical Density: The absorbance values at 450 nm and 620 nm are given by the microplate reader and cannot be changed. OD sample = (A450 - A620) sample. Absorbance values are rounded to 4 decimal places. Each sample is loaded in duplicate. Accuracy (used to evaluate the relative error relative to the theoretical value, abbreviated as %RE) and precision (used to evaluate the relative standard deviation, abbreviated as %CV) are rounded to 1 decimal place. The calculation formula is as follows:
[0520] Precision (%CV) = standard deviation (SD) / mean value of measured concentration × 100%
[0521] Accuracy (%RE) = (average measured concentration - theoretical concentration) / theoretical concentration × 100%
[0522] 4.3 Experimental Data: Thermo Fisher Scientific's Skanit 3.1 analysis software was used to perform four-parameter logistic curve fitting to obtain concentration values. Mean concentration, accuracy, and precision were calculated using Excel's native calculation functions.
[0523] The calibration curve equation is: y = d + (ad) / (1 + (x / c) ^ b)
[0524] The results are shown in Figure 14. As shown in Table 2 and Figure 14, Hz33B9C5 and Hz47E2 have longer in vivo half-lives, which indicates that the antibodies of the present invention improve the pharmacokinetics of anti-CD40L antibodies and have excellent pharmacokinetics.
[0525] Table 2. Pharmacokinetics of anti-CD40L antibodies of the present invention
[0526] Sequence information:
Claims
1. An anti-CD40L antibody or an antigen-binding fragment thereof, the antibody comprising: (i) the three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in the VH as shown in SEQ ID NO:4, and the three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in the VL as shown in SEQ ID NO:10; or (ii) three complementarity determining regions HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO:16, and three complementarity determining regions LCDR1, LCDR2 and LCDR3 contained in VL as shown in SEQ ID NO:
21.
2. An anti-CD40L antibody or an antigen-binding fragment thereof, comprising a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), a third heavy chain complementarity determining region (HCDR3), and a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3), wherein: (i) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise or consist of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9; or (ii) the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or respectively consist of the amino acid sequences shown in SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:
20.
3. The anti-CD40L antibody or antigen-binding fragment thereof of claim 1 or 2, comprising a heavy chain variable region (VH), wherein the heavy chain variable region comprises, consists of, or comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 4 or 16, or consists of said sequence; or it comprises a light chain variable region (VL), wherein the light chain variable region comprises, consists of, or comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10 or 21, or consists of said sequence.
4. An anti-CD40L antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein (i) the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO:4, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO:10, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; or (ii) the heavy chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO:16, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO:21, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
5. The anti-CD40L antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, wherein (i) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 4, and The light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 10; or (ii) the heavy chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO: 16, and the light chain variable region comprises or consists of the amino acid sequence shown in SEQ ID NO:
21. The anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising an Fc region.
7. The anti-CD40L antibody or antigen-binding fragment thereof according to claim 6, wherein the Fc region is derived from human IgG Fc, for example, Fc from human IgG1, Fc from human IgG2, Fc from human IgG3 or Fc from human IgG4.
8. The anti-CD40L antibody or antigen-binding fragment thereof according to claim 7, wherein the Fc region comprises a mutation that reduces or eliminates effector function, and / or a mutation that eliminates binding to FcγR and retains binding affinity to FcRn.
9. The anti-CD40L antibody or antigen-binding fragment thereof according to claim 8, wherein the mutations are L234A / L235A and P329 deletion mutations.
10. The anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 6 to 9, wherein the Fc region (i) comprising or consisting of the amino acid sequence of SEQ ID NO: 23 or 24; (ii) comprises an amino acid sequence that is at least 90% identical, such as 95%, 96%, 97%, 99% or more identical to the amino acid sequence of SEQ ID NO: 23; or (iii) comprising an amino acid sequence having at least 90% identity, such as 95%, 96%, 97%, 99% or higher identity to the amino acid sequence of SEQ ID NO: 24, and comprising L234A / L235A and P329 deletion mutations.
11. The anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, comprising a heavy chain constant region, wherein the heavy chain constant region is derived from the constant region of IgG1, IgG2, IgG3 or IgG4, preferably, the heavy chain constant region (i) comprises or consists of an amino acid sequence selected from SEQ ID NO: 5 or 26; (ii) comprises an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 26; or (iii) comprising an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:5, and having L234A / L235A and P329 deletion mutations.
12. The anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, comprising a light chain constant region, wherein the light chain constant region is a lambda or kappa light chain constant region, preferably, the light chain constant region (i) comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 11; or (ii) comprises the amino acid sequence of SEQ ID NO: 11 or consists of the amino acid sequence.
13. The anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1 to 12, comprising a heavy chain, wherein the heavy chain (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 6 or 17; or (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 6 or 17; or It comprises a light chain, wherein the light chain (i) comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from SEQ ID NO: 12 or 22; or (ii) comprises or consists of an amino acid sequence selected from SEQ ID NO: 12 or 22.
14. An anti-CD40L antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein (i) the heavy chain comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:6; and the light chain comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:12; or (ii) the heavy chain comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:17; and the light chain comprises or consists of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:
22.
15. The anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1 to 14, comprising a heavy chain and a light chain, wherein (i) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 6, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO: 12; (ii) the heavy chain comprises or consists of the amino acid sequence of SEQ ID NO: 17, and the light chain comprises or consists of the amino acid sequence of SEQ ID NO:
22.
16. The anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody is a monoclonal antibody.
17. The anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, wherein the antibody is a humanized antibody or a chimeric antibody.
18. The anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1 to 17, wherein the antigen-binding fragment is an antibody fragment selected from the group consisting of: Fv, Fab, Fab', Fab'-SH, F(ab')2, dAb (domain antibody), linear antibody, single-chain antibody (e.g., scFv); single-domain antibody (sdAb) such as VHH, diabody or fragment thereof, or camelid antibody or diabody.
19. The anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1 to 18, wherein the antibody or antigen-binding fragment thereof has one or more of the following properties: a) binds to CD40L (e.g., human CD40L) with high affinity; b) Inhibit the binding of CD40 to CD40L c) inhibiting CD40 / CD40L signaling pathway; d) inhibit B cell activation or proliferation; e) inhibiting the proliferation of B cells; f) inhibiting B cell maturation and differentiation, such as inhibiting B cell differentiation into plasma cells; g) inhibiting the secretion of IL-12 by dendritic cells; h) does not cause platelet activation; i) treatment or prevention of immune diseases, such as multiple sclerosis (MS); and / or j) inhibiting immune response, preferably humoral immune response, such as inhibiting the production of antibodies k) improved pharmacokinetics, preferably having an in vivo half-life equal to or greater than about 200 hours, more preferably equal to or greater than about 210, 220, 230, 240, 250, 260, 270, 280 or 290 hours.
20. An isolated nucleic acid encoding the anti-CD40L antibody or antigen-binding fragment thereof of any one of claims 1-19.
21. A vector comprising the nucleic acid of claim 20, preferably said vector is an expression vector.
22. A host cell comprising the nucleic acid of claim 20 or the vector of claim 21, preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from yeast cells, mammalian cells (e.g., 293 cells or CHO cells, such as CHO-K cells or HEK293 cells) or other cells suitable for preparing antibodies or antigen-binding fragments thereof.
23. A method for preparing an antibody or antigen-binding fragment thereof that binds to CD40L, the method comprising a) culturing the host cell of claim 22 under conditions suitable for expressing a nucleic acid encoding an anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 19, b) optionally isolating the antibody or antigen-binding fragment thereof, c) Optionally, the method further comprises recovering the anti-CD40L antibody or antigen-binding fragment thereof from the host cell. Optionally, the antibody is purified, for example, purified by Protein A.
24. An immunoconjugate comprising an anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 19 and other substances, such as therapeutic agents, such as active agents that produce biological effects, including but not limited to cytokines, other antibodies, small molecule drugs or immunomodulators (such as immunosuppressants).
25. A pharmaceutical composition comprising the anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 19 or the immunoconjugate according to claim 24, and optionally a pharmaceutically acceptable excipient.
26. A pharmaceutical combination product comprising an anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 19 or an immunoconjugate according to claim 24, and one or more other therapeutic agents, such as active agents that produce biological effects, including but not limited to cytokines, other antibodies, small molecule drugs or immunomodulators (e.g., immunosuppressants).
27. A method for preventing or treating a disease or condition associated with inappropriate activation of a CD40L / CD40-mediated pathway in an individual, the method comprising administering to the subject an effective amount of an anti-CD40L antibody or antigen-binding fragment thereof according to any one of claims 1 to 19, or an immunoconjugate according to claim 24, or a pharmaceutical composition according to claim 25, or a pharmaceutical combination product according to claim 26.
28. The method of claim 27, wherein the subject has abnormal activation of CD40L / CD40-mediated signaling pathways and / or excessive production and deposition of anti-self antibodies compared to healthy individuals; and / or the subject has increased expression of CD40L or CD40 on cells (e.g., activated T cells or other types of immune cells or non-immune cells, such as epithelial cells, monocytes, dendritic cells, fibroblasts, smooth muscle cells, endothelial cells and platelets), e.g., compared to corresponding cells in healthy individuals.
29. The method of claim 27 or 28, wherein the disease or condition is selected from the group consisting of autoimmune diseases, lupus nephritis, immune thrombocytopenic purpura (ITP), transplant rejection, Crohn's disease, inflammatory bowel disease (IBD), colitis, asthma / allergy, atherosclerosis, myasthenia gravis, multiple sclerosis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, coronary heart disease, type 1 diabetes, amyotrophic lateral sclerosis (ALS), and immune responses to recombinant pharmaceutical products such as hemophilia factor VII.
